e10vq
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For quarter ended September 30, 2006
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 1-13252
McKESSON CORPORATION
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
94-3207296
(IRS Employer Identification No.) |
|
|
|
One Post Street, San Francisco, California
(Address of principal executive offices)
|
|
94104
(Zip Code) |
(415) 983-8300
(Registrants telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the Registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated
filer in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer þ Accelerated filer o Non-accelerated filer o
Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of
the Exchange Act. Yes o No þ
Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date.
|
|
|
Class |
|
Outstanding at September 30, 2006 |
Common stock, $0.01 par value
|
|
295,968,992 shares |
McKESSON CORPORATION
PART I. FINANCIAL INFORMATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
March 31, |
|
|
|
2006 |
|
|
2006 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
2,254 |
|
|
$ |
2,139 |
|
Restricted cash |
|
|
981 |
|
|
|
962 |
|
Receivables, net |
|
|
5,983 |
|
|
|
6,247 |
|
Inventories |
|
|
7,791 |
|
|
|
7,127 |
|
Prepaid expenses and other |
|
|
293 |
|
|
|
522 |
|
|
|
|
|
|
|
|
Total |
|
|
17,302 |
|
|
|
16,997 |
|
|
Property, Plant and Equipment, Net |
|
|
634 |
|
|
|
663 |
|
Capitalized Software Held for Sale, Net |
|
|
150 |
|
|
|
139 |
|
Goodwill |
|
|
1,696 |
|
|
|
1,637 |
|
Intangible Assets, Net |
|
|
132 |
|
|
|
116 |
|
Other Assets |
|
|
1,565 |
|
|
|
1,409 |
|
|
|
|
|
|
|
|
Total Assets |
|
$ |
21,479 |
|
|
$ |
20,961 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
Drafts and accounts payable |
|
$ |
10,426 |
|
|
$ |
9,944 |
|
Deferred revenue |
|
|
813 |
|
|
|
827 |
|
Current portion of long-term debt |
|
|
25 |
|
|
|
26 |
|
Securities Litigation |
|
|
1,002 |
|
|
|
1,014 |
|
Other |
|
|
1,664 |
|
|
|
1,679 |
|
|
|
|
|
|
|
|
Total |
|
|
13,930 |
|
|
|
13,490 |
|
|
|
|
|
|
|
|
|
|
Postretirement Obligations and Other Noncurrent Liabilities |
|
|
669 |
|
|
|
599 |
|
Long-Term Debt |
|
|
959 |
|
|
|
965 |
|
|
|
|
|
|
|
|
|
|
Other
Commitments and Contingent Liabilities (Note 14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 100 shares authorized, no
shares issued or outstanding |
|
|
|
|
|
|
|
|
Common stock, $0.01 par value
Shares authorized: September 30, 2006 and March 31, 2006 800
Shares issued: September 30, 2006 335 and March 31, 2006 330 |
|
|
3 |
|
|
|
3 |
|
Additional paid-in capital |
|
|
3,444 |
|
|
|
3,238 |
|
Other capital |
|
|
(33 |
) |
|
|
(75 |
) |
Retained earnings |
|
|
4,248 |
|
|
|
3,871 |
|
Accumulated other comprehensive income |
|
|
94 |
|
|
|
55 |
|
ESOP notes and guarantees |
|
|
(17 |
) |
|
|
(25 |
) |
Treasury shares, at cost, September 30, 2006 39 and March 31,
2006 26 |
|
|
(1,818 |
) |
|
|
(1,160 |
) |
|
|
|
|
|
|
|
Total Stockholders Equity |
|
|
5,921 |
|
|
|
5,907 |
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders Equity |
|
$ |
21,479 |
|
|
$ |
20,961 |
|
|
|
|
|
|
|
|
See Financial Notes
3
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2006 |
|
|
2005 |
|
|
2006 |
|
|
2005 |
|
Revenues |
|
$ |
22,386 |
|
|
$ |
21,253 |
|
|
$ |
45,701 |
|
|
$ |
41,953 |
|
Cost of Sales |
|
|
21,362 |
|
|
|
20,385 |
|
|
|
43,681 |
|
|
|
40,189 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
1,024 |
|
|
|
868 |
|
|
|
2,020 |
|
|
|
1,764 |
|
Operating Expenses |
|
|
724 |
|
|
|
642 |
|
|
|
1,448 |
|
|
|
1,232 |
|
Securities Litigation Charge
(Credit), Net |
|
|
(6 |
) |
|
|
|
|
|
|
(6 |
) |
|
|
52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Operating Expenses |
|
|
718 |
|
|
|
642 |
|
|
|
1,442 |
|
|
|
1,284 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
|
306 |
|
|
|
226 |
|
|
|
578 |
|
|
|
480 |
|
Other Income, Net |
|
|
32 |
|
|
|
35 |
|
|
|
67 |
|
|
|
62 |
|
Interest Expense |
|
|
(22 |
) |
|
|
(22 |
) |
|
|
(45 |
) |
|
|
(47 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Continuing
Operations Before Income
Taxes |
|
|
316 |
|
|
|
239 |
|
|
|
600 |
|
|
|
495 |
|
Income Tax Provision |
|
|
(29 |
) |
|
|
(87 |
) |
|
|
(129 |
) |
|
|
(177 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Continuing
Operations |
|
|
287 |
|
|
|
152 |
|
|
|
471 |
|
|
|
318 |
|
Discontinued Operations, net |
|
|
(6 |
) |
|
|
2 |
|
|
|
(6 |
) |
|
|
7 |
|
Discontinued Operations
gain (loss) on sale, net |
|
|
(52 |
) |
|
|
13 |
|
|
|
(52 |
) |
|
|
13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Discontinued Operations |
|
|
(58 |
) |
|
|
15 |
|
|
|
(58 |
) |
|
|
20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income |
|
$ |
229 |
|
|
$ |
167 |
|
|
$ |
413 |
|
|
$ |
338 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Common Share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.94 |
|
|
$ |
0.48 |
|
|
$ |
1.54 |
|
|
$ |
1.02 |
|
Discontinued operations |
|
|
(0.02 |
) |
|
|
0.01 |
|
|
|
(0.02 |
) |
|
|
0.02 |
|
Discontinued
operations gain
(loss) on sale, net |
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
0.75 |
|
|
$ |
0.53 |
|
|
$ |
1.35 |
|
|
$ |
1.08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.96 |
|
|
$ |
0.49 |
|
|
$ |
1.57 |
|
|
$ |
1.04 |
|
Discontinued operations |
|
|
(0.02 |
) |
|
|
0.01 |
|
|
|
(0.02 |
) |
|
|
0.03 |
|
Discontinued
operations gain
(loss) on sale, net |
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
0.77 |
|
|
$ |
0.54 |
|
|
$ |
1.38 |
|
|
$ |
1.11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends Declared Per
Common Share |
|
$ |
0.06 |
|
|
$ |
0.06 |
|
|
$ |
0.12 |
|
|
$ |
0.12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
305 |
|
|
|
316 |
|
|
|
307 |
|
|
|
315 |
|
Basic |
|
|
298 |
|
|
|
308 |
|
|
|
300 |
|
|
|
305 |
|
See Financial Notes
4
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended September 30, |
|
|
|
2006 |
|
|
2005 |
|
Operating Activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
413 |
|
|
$ |
338 |
|
Discontinued operations, net of income taxes |
|
|
58 |
|
|
|
(20 |
) |
Adjustments to reconcile to net cash provided by (used in)
operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
139 |
|
|
|
125 |
|
Securities Litigation charge (credit), net |
|
|
(6 |
) |
|
|
52 |
|
Deferred taxes |
|
|
70 |
|
|
|
111 |
|
Other non-cash items |
|
|
(15 |
) |
|
|
(9 |
) |
|
|
|
|
|
|
|
Total |
|
|
659 |
|
|
|
597 |
|
|
|
|
|
|
|
|
Effects of changes in: |
|
|
|
|
|
|
|
|
Receivables |
|
|
256 |
|
|
|
58 |
|
Inventories |
|
|
(635 |
) |
|
|
262 |
|
Drafts and accounts payable |
|
|
454 |
|
|
|
1,090 |
|
Deferred revenue |
|
|
12 |
|
|
|
101 |
|
Taxes |
|
|
33 |
|
|
|
12 |
|
Securities Litigation settlement payments |
|
|
(6 |
) |
|
|
(69 |
) |
Proceeds from sale of notes receivable |
|
|
|
|
|
|
28 |
|
Other |
|
|
(88 |
) |
|
|
(77 |
) |
|
|
|
|
|
|
|
Total |
|
|
26 |
|
|
|
1,405 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
685 |
|
|
|
2,002 |
|
|
|
|
|
|
|
|
Investing Activities |
|
|
|
|
|
|
|
|
Property acquisitions |
|
|
(51 |
) |
|
|
(82 |
) |
Capitalized software expenditures |
|
|
(86 |
) |
|
|
(65 |
) |
Acquisitions of businesses, less cash and cash equivalents acquired |
|
|
(95 |
) |
|
|
(573 |
) |
Proceeds from sale of businesses |
|
|
175 |
|
|
|
63 |
|
Other |
|
|
(38 |
) |
|
|
5 |
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(95 |
) |
|
|
(652 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities |
|
|
|
|
|
|
|
|
Repayment of debt |
|
|
(8 |
) |
|
|
(20 |
) |
Capital stock transactions: |
|
|
|
|
|
|
|
|
Issuances |
|
|
191 |
|
|
|
282 |
|
Share repurchases |
|
|
(658 |
) |
|
|
(289 |
) |
ESOP notes and guarantees |
|
|
7 |
|
|
|
9 |
|
Dividends paid |
|
|
(36 |
) |
|
|
(36 |
) |
Other |
|
|
29 |
|
|
|
(101 |
) |
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(475 |
) |
|
|
(155 |
) |
Net increase in cash and cash equivalents |
|
|
115 |
|
|
|
1,195 |
|
Cash and cash equivalents at beginning of period |
|
|
2,139 |
|
|
|
1,800 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
2,254 |
|
|
$ |
2,995 |
|
|
|
|
|
|
|
|
See Financial Notes
5
McKESSON CORPORATION
FINANCIAL NOTES
(Unaudited)
1. Significant Accounting Policies
Basis of Presentation. The condensed consolidated financial statements of McKesson
Corporation (McKesson, the Company, or we and other similar pronouns) include the financial
statements of all majority-owned or controlled companies. Significant intercompany transactions
and balances have been eliminated. In our opinion, these unaudited condensed consolidated
financial statements include all adjustments necessary for a fair presentation of the Companys
financial position as of September 30, 2006, and the results of operations for the quarters and six
months ended September 30, 2006 and 2005 and cash flows for the six months ended September 30, 2006
and 2005.
The results of operations for the quarters and six months ended September 30, 2006 and 2005
are not necessarily indicative of the results that may be expected for the entire year. These
interim financial statements should be read in conjunction with the annual audited financial
statements, accounting policies and financial notes included in our 2006 consolidated financial
statements previously filed with the Securities and Exchange Commission (SEC).
The Companys fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all
references to a particular year shall mean the Companys fiscal year. Certain prior year amounts
have been reclassified to conform to the current year presentation.
New Accounting Pronouncements. On April 1, 2006, we adopted Statement of Financial Accounting
Standards (SFAS) No. 123(R), Share-Based Payment, which requires the recognition of expense
resulting from transactions in which we acquire goods and services by issuing our shares, share
options, or other equity instruments. This standard requires a fair-value based measurement method
in accounting for share-based payment transactions. The share-based compensation expense is
recognized for the portion of the awards that is ultimately expected to vest. This standard
replaced SFAS No. 123, Accounting for Stock-Based Compensation, and superseded Accounting
Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees. Accordingly,
the use of the intrinsic value method as provided under APB Opinion No. 25, which was utilized by
the Company, was eliminated. We adopted SFAS No. 123(R) using the modified prospective method of
transition. See Financial Note 4, Share-Based Payment, for further details.
As a result of the provisions of SFAS No. 123(R), in 2007, we now expect share-based compensation
charges to approximate $0.10 to $0.12 per diluted share,
or an increase of $0.02 per diluted share from our previous
expectations. These charges are now expected to be
approximately $0.07 to $0.09 per
diluted share more than the share-based compensation expense recognized in our net income in 2006.
Our assessments of estimated compensation charges are affected by our stock price as well as
assumptions regarding a number of complex and subjective variables and the related tax impact.
These variables include, but are not limited to, the volatility of our stock price, employee stock
option exercise behaviors, timing, level and types of our grants of annual share-based awards and
the attainment of performance goals. As a result, the actual share-based compensation expense in
2007 may differ from the Companys current estimate.
In July 2006, the Financial Accounting Standards Board (FASB) issued Financial
Interpretation (FIN) No. 48, Accounting for Uncertainty in Income Taxes, which clarifies the
accounting for uncertainty in income taxes recognized in the financial statements in accordance
with SFAS No. 109, Accounting for Income Taxes. FIN No. 48 provides that a tax benefit from an
uncertain tax position may be recognized when it is more likely than not that the position will be
sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides
guidance on measurement, derecognition, classification, interest and penalties, accounting in
interim periods, disclosure and transition. FIN No. 48 will become effective for us in 2008. We
are currently assessing the impact of FIN No. 48 on our consolidated financial statements.
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, which defines fair
value, establishes a framework for measuring fair value, and expands disclosures about fair value
measurements. This standard applies under other accounting pronouncements that require or permit
fair value measurements, but does not require any new fair value measurements. SFAS No. 157 will
become effective for us in 2009. We are currently assessing the impact of SFAS No. 157; however,
we do not believe the adoption of this standard will have a material effect on our consolidated
financial statements.
6
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
In September 2006, the FASB issued SFAS No. 158, Employers Accounting for Defined Benefit
Pension and Other Postretirement Plans, which requires us to recognize the funded status of our
defined benefit plans in the consolidated balance sheets and changes in the funded status in
comprehensive income. This standard also requires us to recognize the gains/losses, prior year
service costs and transition assets/obligations as a component of other comprehensive income upon
adoption, and provide additional annual disclosure. SFAS No.158 does not affect the computation of
benefit expense recognized in our consolidated statements of operations. The recognition and
disclosure provisions are effective in 2007. In addition, SFAS No. 158 requires us to measure plan
assets and benefit obligations as of the year-end balance sheet date effective in 2009. We are
required to apply the provisions of this standard prospectively. We are currently assessing the
impact of SFAS No. 158 on our consolidated financial statements.
In September 2006, the SEC staff issued Staff Accounting Bulletin (SAB) No. 108,
Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year
Financial Statements. This guidance indicates that the materiality of a misstatement must be
evaluated using both the rollover and iron curtain approaches. The iron curtain approach
quantifies a misstatement based on the effects of correcting the misstatement existing in the
balance sheet at the end of the current year, while the rollover approach quantifies a misstatement
based on the amount of the error originating in the current year income statement. SAB No. 108 is
effective for our 2007 annual consolidated financial statements. We are currently assessing the
impact of SAB No. 108; however, we do not believe the adoption of this standard will have a
material effect on our consolidated financial statements.
2. Acquisitions and Investments
In the first half of 2007, we acquired the following three entities for a total cost of $91
million, which was paid in cash:
|
|
Sterling Medical Services LLC (Sterling), based in Moorestown,
New Jersey, a national provider and distributor of medical
disposable supplies, health management services and quality
management programs to the home care market. Financial results
for Sterling are included in our Medical-Surgical Solutions
segment; |
|
|
|
HealthCom Partners LLC (HealthCom), based in Mt. Prospect,
Illinois, a leading provider of patient billing solutions designed
to simplify and enhance healthcare providers financial
interactions with their patients; and |
|
|
|
RelayHealth Corporation (RelayHealth), based in Emeryville,
California, a provider of secure online healthcare communication
services linking patients, healthcare professionals, payors and
pharmacies. Financial results for HealthCom and RelayHealth are
included in our Provider Technologies segment. |
Goodwill recognized in these transactions amounted to $60 million.
In addition, in the first quarter of 2007, we contributed $36 million in cash and $45 million
in net assets primarily from our Automated Prescription Systems business to Parata Systems, LLC
(Parata), in exchange for a significant minority interest in Parata. In connection with the
investment, we abandoned certain assets which resulted in a $15 million charge to cost of sales and
we incurred $6 million of other expenses related to the transaction which were recorded within
operating expenses. We did not recognize any additional gains or losses as a result of this
transaction as we believe the fair value of our investment in Parata, as determined by a
third-party valuation, approximates the carrying value of consideration contributed to Parata. Our
investment in Parata is accounted for under the equity method of accounting within our
Pharmaceutical Solutions segment.
In 2006, we made the following acquisitions:
|
|
In the second quarter of 2006, we acquired all of the issued and
outstanding stock of D&K Healthcare Resources, Inc. (D&K) of St.
Louis, Missouri, for an aggregate cash purchase price of $479
million, including the assumption of D&Ks debt. D&K is primarily
a wholesale distributor of branded and generic pharmaceuticals and
over-the-counter health and beauty products to independent and
regional pharmacies, primarily in the Midwest. Approximately $158
million of the purchase price has been assigned to goodwill.
Included in the purchase price were acquired identifiable
intangibles of $43 million primarily representing
|
7
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
customer lists and not-to-compete covenants which have an estimated
weighted-average useful life of nine years. Financial results for D&K are
included in our Pharmaceutical Solutions segment.
|
|
Also in the second quarter of 2006, we acquired all
of the issued and outstanding shares of Medcon, Ltd.
(Medcon), an Israeli company, for an aggregate
purchase price of $82 million. Medcon provides
web-based cardiac image and information management
services to healthcare providers. Approximately $60
million of the purchase price was assigned to
goodwill and $20 million was assigned to intangibles
which represent technology assets and customer lists
which have an estimated weighted-average useful life
of four years. Financial results for Medcon are
included in our Provider Technologies segment. |
During the last two years, we also completed a number of other acquisitions and investments
within all three of our operating segments. Financial results for our business acquisitions have
been included in our consolidated financial statements since their respective acquisition dates.
Purchase prices for our business acquisitions have been allocated based on estimated fair values at
the date of acquisition and, for certain recent acquisitions, may be subject to change. Goodwill
recognized for our business acquisitions is not expected to be deductible for tax purposes. Pro
forma results of operations for our business acquisitions have not been presented because the
effects were not material to the consolidated financial statements on either an individual or an
aggregate basis.
3. Discontinued Operations
Results from discontinued operations were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
September 30, |
|
September 30, |
(In millions) |
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
Income (loss) from
discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acute Care |
|
$ |
(10 |
) |
|
$ |
3 |
|
|
$ |
(10 |
) |
|
$ |
10 |
|
BioServices |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 |
|
Income taxes |
|
|
4 |
|
|
|
(1 |
) |
|
|
4 |
|
|
|
(5 |
) |
|
|
|
Total |
|
$ |
(6 |
) |
|
$ |
2 |
|
|
$ |
(6 |
) |
|
$ |
7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain (loss) on sale of
discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acute Care |
|
$ |
(49 |
) |
|
$ |
|
|
|
$ |
(49 |
) |
|
$ |
|
|
BioServices |
|
|
|
|
|
|
22 |
|
|
|
|
|
|
|
22 |
|
Other |
|
|
6 |
|
|
|
|
|
|
|
6 |
|
|
|
|
|
Income taxes |
|
|
(9 |
) |
|
|
(9 |
) |
|
|
(9 |
) |
|
|
(9 |
) |
|
|
|
Total |
|
$ |
(52 |
) |
|
$ |
13 |
|
|
$ |
(52 |
) |
|
$ |
13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued
operations, net of
taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acute Care |
|
$ |
(67 |
) |
|
$ |
2 |
|
|
$ |
(67 |
) |
|
$ |
6 |
|
PBI |
|
|
5 |
|
|
|
|
|
|
|
5 |
|
|
|
|
|
BioServices |
|
|
|
|
|
|
13 |
|
|
|
|
|
|
|
14 |
|
Other |
|
|
4 |
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
|
Total |
|
$ |
(58 |
) |
|
$ |
15 |
|
|
$ |
(58 |
) |
|
$ |
20 |
|
|
|
|
In July 2006, we signed an agreement to sell our Medical-Surgical Solutions segments Acute
Care supply business to Owens & Minor, Inc. (OMI) for net cash proceeds of approximately $160 million,
subject to certain adjustments. This transaction closed on September 30, 2006. In accordance with
SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the financial
results of this business are classified as a discontinued operation for all periods presented in
the accompanying condensed consolidated financial statements. Such presentation includes the
classification of all applicable assets of the disposed business under the caption Prepaid
expenses and other and all applicable liabilities under the caption Other under Current
Liabilities
8
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
within our condensed consolidated balance sheets for all periods presented. Revenues
associated with the Acute Care business were $274 million and
$260 million for the second quarters of 2007 and 2006, and $573 million and
$528 million for the first halves of 2007 and 2006.
Financial results for this discontinued operation include an after-tax loss of $67 million,
which primarily consists of an after-tax loss of $61 million for the business disposition and $6
million of after-tax losses associated with operations, other asset impairment charges and employee
severance costs. The after-tax loss of $61 million for the business disposition includes a $79
million non-tax deductible write-off of goodwill, as further described below.
In
connection with this divestiture, we allocated a portion of our Medical-Surgical Solutions
segments goodwill to the Acute Care business as required by
SFAS No. 142, Goodwill and Other
Intangible Assets. The allocation was based on the relative fair values of the Acute Care
business and the continuing businesses that are being retained by the Company. The fair value of
the Acute Care business was determined based on the net cash proceeds resulting from the divestiture and
the fair value of the continuing businesses was determined by a third-party valuation. As a result, we
allocated $79 million of the segments goodwill to the Acute Care business.
Additionally, as part of the divestiture, we entered into a transition services agreement
(TSA) with OMI under which we will continue to provide certain services to the Acute Care
business during a transition period of approximately nine months. We also anticipate incurring
approximately $6 million of pre-tax employee severance charges over the transition period. These
charges, as well as the financial results from the TSA, will be recorded as part of discontinued
operations. The continuing cash flows generated from the TSA are not anticipated to be material to
our condensed consolidated financial statements.
In the second quarter of 2007,
we also sold a wholly-owned subsidiary, Pharmaceutical Buyers Inc. (PBI), for
net cash proceeds of $10 million. The divestiture resulted in an after-tax gain of $5 million resulting
from the tax basis of the subsidiary exceeding its carrying value. Financial results of this
business, which were previously included in our Pharmaceutical Solutions segment, have been
presented as a discontinued operation for all periods presented in the accompanying condensed
consolidated financial statements. These results were not material to our condensed consolidated
financial statements.
Results for discontinued operations for 2007 also include an after-tax gain of $4 million
associated with the collection of a note receivable from a business sold in 2003.
In
the second quarter of 2006, we sold our wholly-owned subsidiary, McKesson BioServices
Corporation (BioServices), for net cash proceeds of $63 million. The divestiture resulted in an
after-tax gain of $13 million. Financial results for this business, which were previously included
in our Pharmaceutical Solutions segment, have been presented as a discontinued operation for all
periods presented in the accompanying condensed consolidated financial statements. These results
were not material to our condensed consolidated financial statements.
4. Share-Based Payment
We provide various share-based compensation for our employees, officers and non-employee
directors, including stock options, an employee stock purchase plan, restricted stock (RS),
restricted stock units (RSUs) and performance-based restricted stock units (PeRSUs)
(collectively, share-based.) On April 1, 2006, we adopted SFAS No. 123(R), as discussed in
Financial Note 1, Significant Accounting Policies. Accordingly, we began to recognize
compensation expense for the fair value of share-based awards granted, modified, repurchased or
cancelled from April 1, 2006 forward. For the unvested portion of awards issued prior to and
outstanding as of April 1, 2006, the expense is recognized at the grant-date fair value as the
remaining requisite service is rendered. We recognize compensation expense on a straight-line
basis over the requisite service period for those awards with graded vesting and service
conditions. For the awards with performance conditions, we recognize the expense on a
straight-line basis, treating each vesting tranche as a separate award. In 2006, 2005 and 2004, we
reduced the vesting period of substantially all of the then outstanding stock options for employee
retention purposes and in anticipation of the requirements of SFAS No. 123(R), either through
acceleration or shortened vesting schedules at grant. We adopted SFAS No. 123(R) using the
modified prospective method and therefore have not restated prior period financial statements.
Prior to adopting SFAS No. 123(R), we accounted for our employee share-based
9
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
compensation plans using the intrinsic value method under APB Opinion No. 25. This standard
generally did not require recognition of compensation expense for the majority of our share-based
awards except for RS and RSUs. In addition, as required under APB Opinion No. 25, we previously
recognized forfeitures as they occurred.
The compensation expense recognized under SFAS No. 123(R) has been classified in the income
statement or capitalized on the balance sheet in the same manner as cash compensation paid to our
employees. There was no material share-based compensation expense capitalized as part of the
balance sheet at September 30, 2006. In addition, SFAS No. 123(R) requires that the benefits of
realized tax deductions in excess of previously recognized tax benefits on compensation expense be
reported as a financing cash flow rather than an operating cash flow, as was done under APB Opinion
No. 25. For the quarter and six months ended September 30, 2006, $27 million and $36 million of
excess tax benefits were recognized.
In conjunction with the adoption of SFAS No. 123(R), we elected the short-cut method for
calculating the beginning balance of the additional paid-in capital pool (APIC pool) related to
the tax effects of share-based compensation. Under this method, a simplified calculation is
applied in establishing the beginning APIC pool balance as well as determining the future impact on
the APIC pool and our consolidated statements of cash flows relating to the tax effects of
share-based compensation. The election of this accounting policy did not have a material impact on
our consolidated financial statements.
I. Impact on Net Income
During the second quarter and first half of 2007, we recorded $16 million and $24 million of
pre-tax share-based compensation expense, compared to $25 million and $32 million pre-tax pro forma
expense for the comparable prior year periods. The share-based compensation expense for the second
quarter and first half of 2007 was comprised of RS, RSUs and PeRSUs expense of $12 million and $20
million, stock option expense of $2 million and $3 million, and employee stock purchase plan
expense of $2 million and $4 million. The amount for the first half of 2007 also included a credit
of $3 million for a cumulative effect adjustment to reflect estimated forfeitures relating to
unvested RS and RSUs outstanding upon the adoption of SFAS No. 123(R). We recognized tax benefits
related to the share-based compensation of $6 million and $8 million in the second quarter and
first half of 2007.
The following table illustrates the impact of share-based compensation on reported amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
September 30, 2006 |
|
September 30, 2006 |
|
|
|
|
|
|
Impact of |
|
|
|
|
|
Impact of |
|
|
|
|
|
|
Share-Based |
|
|
|
|
|
Share-Based |
(In millions, except per share data) |
|
As Reported |
|
Compensation |
|
As Reported |
|
Compensation |
|
Income from continuing operations
before income taxes |
|
$ |
316 |
|
|
$ |
16 |
|
|
$ |
600 |
|
|
$ |
24 |
|
Net income |
|
|
229 |
|
|
|
10 |
|
|
|
413 |
|
|
|
16 |
|
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
$ |
0.75 |
|
|
$ |
0.03 |
|
|
$ |
1.35 |
|
|
$ |
0.05 |
|
Basic |
|
|
0.77 |
|
|
|
0.03 |
|
|
|
1.38 |
|
|
|
0.05 |
|
|
10
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
II. SFAS No. 123 Pro Forma Information for 2006
As noted above, prior to April 1, 2006 we accounted for our employee share-based compensation
plans using the intrinsic value method under APB Opinion No. 25. Had compensation expense for our
employee share-based compensation been recognized based on the fair value method, consistent with
the provisions of SFAS No. 123, net income and earnings per share would have been as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months |
|
|
Quarter Ended |
|
Ended |
|
|
September 30, |
|
September 30, |
(In millions, except per share data) |
|
2005 |
|
2005 |
|
Net income, as reported |
|
$ |
167 |
|
|
$ |
338 |
|
Share-based compensation expense
included in reported net income, net of
income taxes |
|
|
2 |
|
|
|
4 |
|
Share-based compensation expense
determined under the fair value method,
net of income taxes |
|
|
(16 |
) |
|
|
(20 |
) |
|
|
|
Pro forma net income |
|
$ |
153 |
|
|
$ |
322 |
|
|
|
|
Earnings per common share: |
|
|
|
|
|
|
|
|
Diluted as reported |
|
$ |
0.53 |
|
|
$ |
1.08 |
|
Diluted pro forma |
|
|
0.48 |
|
|
|
1.03 |
|
Basic as reported |
|
|
0.54 |
|
|
|
1.11 |
|
Basic pro forma |
|
|
0.50 |
|
|
|
1.06 |
|
|
III. Stock Plans
The 2005 Stock Plan (the 2005 Plan) provides our employees, officers and non-employee
directors share-based long-term incentives. The 2005 Plan permits the granting of stock options,
RS, RSUs, PeRSUs and other share-based awards. Under the 2005 Plan, 13 million shares were
authorized for issuance, and as of September 30, 2006, 5 million shares remain available for future
grant. The 2005 Plan replaced the following three plans in advance of their expirations: 1999
Stock Option and Restricted Stock Plan, the 1997 Directors Equity Compensation and Deferral Plan
and the 1998 Canadian Incentive Plan (collectively, the Legacy Plans). The aggregate remaining
11 million authorized shares under the Legacy Plans were cancelled, although awards under those
plans remain outstanding. The 2005 Plan is now the Companys only plan for providing share-based
incentive compensation to employees and non-employee directors of the Company and its affiliates.
In anticipation of the requirements of SFAS No. 123(R), the Compensation Committee of the
Companys Board of Directors (Compensation Committee) reviewed our long-term compensation program
for key employees across the Company. As a result, beginning in 2006, reliance on options was
reduced with more long-term incentive value delivered by grants of PeRSUs and performance-based
cash compensation.
IV. Stock Options
Stock options are granted at not less than fair market value and those options granted under
the 2005 Plan have a contractual term of seven years. Prior to 2004, stock options typically
vested over a four-year period and had a contractual term of ten years. As noted above, in 2006,
2005 and 2004, we reduced the vesting period of substantially all of the then outstanding unvested
stock options, either through acceleration or shortened vesting schedules at grant. It is expected
that options granted in 2007 and future years will have a seven-year contractual life and generally
follow the four-year vesting schedule. Stock options under the Legacy Plans, which are
substantially vested, generally have a ten-year contractual life.
11
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
Compensation expense for stock options is recognized on a straight-line basis over the
requisite service period and is based on the grant-date fair value for the portion of the awards
that is ultimately expected to vest. We continue to use the Black-Scholes model to estimate the
fair value of our stock options. Once the fair value of an employee stock option value is
determined, current accounting practices do not permit it to be changed, even if the estimates used
are different from actual. The option pricing model requires the use of various estimates and
assumptions, as follows:
|
|
Expected stock price volatility is based on a combination of historical volatility of our common stock and implied
market volatility. We believe that this market-based input provides a better estimate of our future stock price
movements and is consistent with emerging employee stock option valuation considerations. Our expected stock price
volatility assumption continues to reflect a constant dividend yield during the expected term of the option. |
|
|
|
Expected dividend yield is based on historical experience and investors current expectations. |
|
|
|
The risk-free interest rate for periods within the expected life of the option is based on the constant maturity U.S.
Treasury rate in effect at the time of grant. |
|
|
|
The expected life of the options is determined based on historical option exercise behavior data, and also reflects the
impact of changes in contractual life of current option grants compared to our historical grants. |
Weighted-average assumptions used to estimate the fair value of employee stock options were as
follows:
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
2006 |
|
Expected stock price volatility |
|
|
27 |
% |
|
|
36 |
% |
Expected dividend yield |
|
|
0.5 |
% |
|
|
0.5 |
% |
Risk-free interest rate |
|
|
5 |
% |
|
|
4 |
% |
Expected life (in years) |
|
|
5 |
|
|
|
6 |
|
|
The estimated forfeiture rate, which reduces the expense, is based on historical experience.
The estimated forfeiture rate at grant will be re-assessed at least annually and revised if actual
forfeitures differ materially from those estimates. In addition, the forfeiture estimates will be
adjusted to reflect actual forfeitures when an award vests. In the Companys pro forma information
required under SFAS No. 123 for the periods prior to 2007, we accounted for forfeitures as they
occurred. We expect forfeitures to approximate 8% per annum. The actual forfeitures in the future
reporting periods could be materially higher or lower than our current estimates. As a result, the
share-based compensation expense in 2007 may differ from the Companys current estimate.
The following table summarizes stock option activity during the first half of 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
Weighted- |
|
Remaining |
|
Aggregate |
|
|
|
|
|
|
Average Exercise |
|
Contractual |
|
Intrinsic |
(In millions, except per share data) |
|
Shares |
|
Price |
|
Term (Years) |
|
Value (2) |
|
Outstanding, April 1, 2006 |
|
|
46 |
|
|
$ |
43.38 |
|
|
|
|
|
|
|
|
|
Granted |
|
|
1 |
|
|
|
48.12 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(5 |
) |
|
|
33.10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding, September 30, 2006 |
|
|
42 |
|
|
|
44.72 |
|
|
|
4 |
|
|
$ |
552 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest (1),
September 30, 2006 |
|
|
42 |
|
|
|
44.72 |
|
|
|
4 |
|
|
|
552 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable, September 30, 2006 |
|
|
40 |
|
|
|
44.80 |
|
|
|
4 |
|
|
|
534 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The number of options expected to vest takes into account an estimate of expected
forfeitures. |
|
(2) |
|
The aggregate intrinsic value is calculated as the difference between the period-end market
price of the Companys stock
and the option exercise price, times the number of in-the-money option shares. |
12
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
The total intrinsic value of
stock options exercised during the second quarters and first
halves of 2007 and 2006 was $69 million and $58 million and $92 million and $109 million. The total
fair value of stock options vested in the second quarter and first
half of 2007 was nil and $1
million. The weighted average grant-date fair value of stock options granted during the second
quarters and first halves of 2007 and 2006 was $16.13 and $18.30 and $15.43 and $18.24. Cash
received from the exercise of stock options in the second quarters
and first halves of 2007 and 2006
was $117 million and $113 million and $167 million and $268 million, and the related tax benefits
realized were $27 million and $29 million and $35 million and $48 million. Total compensation
expense, net of estimated forfeitures, related to unvested stock options not yet recognized at
September 30, 2006 was approximately $21 million, and the weighted-average period over which the
cost is expected to be recognized is 3 years.
V. RS, RSUs and PeRSUs
RS and RSUs, which entitle the holder to receive, at the end of a vesting term, a specified
number of shares of the Companys common stock, are accounted for at fair value at the date of
grant. The fair value of RS and RSUs under our stock plans is determined by the product of the
number of shares that are expected to vest and the grant date market price of the Companys common
stock. The Compensation Committee determines the vesting terms at the time of grant. These awards
generally vest in full after three years. The fair value of RS and RSUs with graded vesting and
service conditions is expensed on a straight-line basis over the requisite service period. RS
contains certain restrictions on transferability and may not be transferred until such restrictions
lapse.
Each non-employee director currently receives 2,500 RSUs annually, which vest immediately, and
which are expensed upon grant. However, issuance of any shares is delayed until the director is no
longer performing services for the Company. At September 30, 2006, 40,000 RSUs for our directors
are vested, but shares have not been issued.
PeRSUs are RSUs for which the number of RSUs awarded may be conditional upon the attainment of
one or more performance objectives over a specified period. Vesting of such awards ranges from one
to three-year periods following the end of the performance period and may follow the graded or
cliff method of vesting.
PeRSUs are accounted for as variable awards until the performance goals are reached and the
grant date is established. The fair value of PeRSUs is determined by the product of the number of
shares eligible to be awarded and expected to vest, and the market price of the Companys common
stock, commencing at the inception of the requisite service period. During the performance period,
the PeRSUs are re-valued using the market price and the performance modifier at the end of a
reporting period. At the end of the performance period, if the goals are attained, the award is
classified as a RSU and is accounted for on that basis. The fair value of PeRSUs is expensed on a
straight-line basis, treating each vesting tranche as a separate award, over the requisite service
period of four years. For RS and RSUs with service conditions, we have elected to amortize the
expense on a straight-line basis.
The following table summarizes RS and RSU activity during the first half of 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
Average |
|
|
|
|
|
|
Grant Date Fair |
(In millions, except per share data) |
|
Shares |
|
Value Per Share |
|
Nonvested, April 1, 2006 |
|
|
1 |
|
|
$ |
37.09 |
|
Granted |
|
|
1 |
|
|
|
48.17 |
|
|
|
|
|
|
|
|
|
|
Nonvested, September 30, 2006 |
|
|
2 |
|
|
|
43.82 |
|
|
The total fair value of shares vested during the second quarter and first half of 2007 was $1
million and $4 million. As of September 30, 2006, the total compensation cost, net of estimated
forfeitures, related to nonvested RS and RSU awards not yet recognized was approximately $33
million, pre-tax, and the weighted-average period over which the cost is expected to be recognized
is 3 years.
In May 2006, the Compensation Committee approved 1 million PeRSU target share units
representing the base number of awards that could be granted, if goals are attained, and would be
granted in the first quarter of 2008 (the 2007 PeRSU). These target share units are not included
in the table above as they have not been granted in the
13
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
form of a RSU. As of September 30, 2006,
the total compensation cost, net of estimated forfeitures, related to nonvested 2007 PeRSUs not yet
recognized was approximately $53 million, pre-tax (based on the period-end market price of the
Companys common stock), and the weighted-average period over which the cost is expected to be
recognized is 3 years.
In accordance with the provisions of SFAS No. 128, Earnings per Share, the 2007 PeRSUs are
not included in the calculation of diluted weighted average shares until the performance goals have
been achieved.
VI. Employee Stock Purchase Plan (ESPP)
The ESPP allows eligible employees to purchase shares of our common stock through payroll
deductions. The deductions occur over three-month purchase periods and the shares are then
purchased at 85% of the market price at the end of each purchase period. Employees are allowed to
terminate their participation in the ESPP at any time during the purchase period prior to the
purchase of the shares, and any amounts accumulated during that period are refunded.
The 15% discount provided to employees on these shares is included in compensation expense.
The funds outstanding at the end of a quarter are included in the calculation of diluted weighted
average shares outstanding. These amounts have not been significant.
5. Income Taxes
During the second quarter of 2007, we recorded a credit to income tax expense of $83 million
which primarily pertains to our receipt of a private letter ruling from the U.S. Internal Revenue
Service (IRS) holding that our payment of approximately $960 million to settle our Securities
Litigation Consolidated Action is fully tax-deductible. We previously established tax reserves to
reflect the lack of certainty regarding the tax deductibility of settlement amounts paid in the
Consolidated Action and related litigation.
6. Restructuring Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
Provider |
|
|
|
|
Solutions |
|
Technologies |
|
|
(In millions) |
|
Severance |
|
Exit-Related |
|
Severance |
|
Total |
|
Balance, March 31, 2006 |
|
$ |
6 |
|
|
$ |
30 |
|
|
$ |
|
|
|
$ |
36 |
|
Expenses |
|
|
1 |
|
|
|
|
|
|
|
6 |
|
|
|
7 |
|
Cash expenditures |
|
|
(4 |
) |
|
|
(6 |
) |
|
|
(4 |
) |
|
|
(14 |
) |
Adjustment to liabilities
related to the acquisition
of D&K |
|
|
|
|
|
|
(14 |
) |
|
|
|
|
|
|
(14 |
) |
|
|
|
Balance, September 30, 2006 |
|
$ |
3 |
|
|
$ |
10 |
|
|
$ |
2 |
|
|
$ |
15 |
|
|
During the first half of 2007, we recorded pre-tax restructuring expense of $7 million, which
primarily reflected employee termination costs within our Provider Technologies segment. This
segments restructuring plan was intended to realign product development and marketing resources.
Approximately 125 employees were terminated as part of this plan.
In connection with the D&K acquisition, in 2006 we recorded $10 million of liabilities
relating to employee severance costs and $28 million for facility exit and contract termination
costs. Approximately 260 employees, consisting primarily of distribution, general and
administrative staff, were terminated as part of this restructuring plan. To date, $8 million of
severance and $7 million of exit costs have been paid. In connection with the Companys investment
in Parata, $13 million of contract termination costs that were initially estimated as part of the
D&K acquisition were extinguished and, as a result, the Company decreased goodwill and decreased
its
restructuring liability during the first half of 2007. At September 30, 2006, the remaining
severance liability for this plan was $2 million, which is anticipated to be paid by the end of
2007, and the remaining facility exit liability was $7 million, which is anticipated to be paid at
various dates through 2015.
14
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
7. Earnings Per Share
Basic earnings per share is computed by dividing net income by the weighted average number of
common shares outstanding during the reporting period. Diluted earnings per share is computed
similarly except that it reflects the potential dilution that could occur if dilutive securities or
other obligations to issue common stock were exercised or converted into common stock.
The computations for basic and diluted earnings per share are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
September 30, |
|
September 30, |
(In millions, except per share data) |
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
Income from continuing operations |
|
$ |
287 |
|
|
$ |
152 |
|
|
$ |
471 |
|
|
$ |
318 |
|
Interest expense on convertible junior
subordinated debentures, net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
Income from continuing operations
diluted |
|
|
287 |
|
|
|
152 |
|
|
|
471 |
|
|
|
319 |
|
Discontinued operations |
|
|
(6 |
) |
|
|
2 |
|
|
|
(6 |
) |
|
|
7 |
|
Discontinued operations gain (loss) on
sale, net |
|
|
(52 |
) |
|
|
13 |
|
|
|
(52 |
) |
|
|
13 |
|
|
|
|
Net income diluted |
|
$ |
229 |
|
|
$ |
167 |
|
|
$ |
413 |
|
|
$ |
339 |
|
|
|
|
Weighted average common shares
outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
298 |
|
|
|
308 |
|
|
|
300 |
|
|
|
305 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options to purchase common stock |
|
|
6 |
|
|
|
8 |
|
|
|
6 |
|
|
|
7 |
|
Convertible junior subordinated
debentures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 |
|
Restricted stock |
|
|
1 |
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
Diluted |
|
|
305 |
|
|
|
316 |
|
|
|
307 |
|
|
|
315 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Common Share: (1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.94 |
|
|
$ |
0.48 |
|
|
$ |
1.54 |
|
|
$ |
1.02 |
|
Discontinued operations, net |
|
|
(0.02 |
) |
|
|
0.01 |
|
|
|
(0.02 |
) |
|
|
0.02 |
|
Discontinued operations gain
(loss) on sale, net |
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
|
Total |
|
$ |
0.75 |
|
|
$ |
0.53 |
|
|
$ |
1.35 |
|
|
$ |
1.08 |
|
|
|
|
Basic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.96 |
|
|
$ |
0.49 |
|
|
$ |
1.57 |
|
|
$ |
1.04 |
|
Discontinued operations, net |
|
|
(0.02 |
) |
|
|
0.01 |
|
|
|
(0.02 |
) |
|
|
0.03 |
|
Discontinued operations gain
(loss) on sale, net |
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
(0.17 |
) |
|
|
0.04 |
|
|
|
|
Total |
|
$ |
0.77 |
|
|
$ |
0.54 |
|
|
$ |
1.38 |
|
|
$ |
1.11 |
|
|
|
|
|
(1) |
|
Certain computations may reflect rounding adjustments. |
Approximately 11 million and 12 million stock options were excluded from the computations
of diluted net earnings per share for the quarters ended September 30, 2006 and 2005 as their
exercise price was higher than the Companys average stock price. For the six months ended
September 30, 2006 and 2005, the number of stock options excluded was approximately 12 million and
17 million.
15
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
8. Goodwill and Intangible Assets, Net
Changes in the carrying amount of goodwill for the six months ended September 30, 2006 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
Medical-Surgical |
|
Provider |
|
|
(In millions) |
|
Solutions |
|
Solutions |
|
Technologies |
|
Total |
|
Balance, March 31, 2006 |
|
$ |
495 |
|
|
$ |
672 |
|
|
$ |
470 |
|
|
$ |
1,637 |
|
Goodwill acquired, net of
purchase price adjustments |
|
|
(18 |
) |
|
|
21 |
|
|
|
43 |
|
|
|
46 |
|
Translation adjustments |
|
|
2 |
|
|
|
|
|
|
|
11 |
|
|
|
13 |
|
|
|
|
Balance, September 30, 2006 |
|
$ |
479 |
|
|
$ |
693 |
|
|
$ |
524 |
|
|
$ |
1,696 |
|
|
Information regarding intangible assets is as follows:
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
March 31, |
(In millions) |
|
2006 |
|
2006 |
|
Customer lists |
|
$ |
159 |
|
|
$ |
139 |
|
Technology |
|
|
94 |
|
|
|
83 |
|
Trademarks and other |
|
|
42 |
|
|
|
40 |
|
|
|
|
Gross intangibles |
|
|
295 |
|
|
|
262 |
|
Accumulated amortization |
|
|
(163 |
) |
|
|
(146 |
) |
|
|
|
Intangible assets, net |
|
$ |
132 |
|
|
$ |
116 |
|
|
Amortization expense of other intangibles was $11 million and $19 million for the quarter and
six months ended September 30, 2006 and $6 million and $12 million for the quarter and six months
ended September 30, 2005. The weighted average remaining amortization periods for customer lists,
technology and trademarks and other intangible assets at September 30, 2006 were: 8 years, 4 years
and 4 years. Estimated future annual amortization expense of these assets is as follows: $18
million, $28 million, $19 million, $11 million and $8 million for 2007 through 2011, and $28
million thereafter. At September 30, 2006, there was $20 million of other intangibles not subject
to amortization.
9. Financing Activities
In June 2006, we renewed our committed accounts receivable sales facility. The facility was
renewed under substantially similar terms to those previously in place with the exception that the
facility amount was reduced to $700 million from $1.4 billion. The renewed facility expires in
June 2007. At September 30, 2006 and March 31, 2006,
there were no amounts outstanding under any of
our borrowing facilities.
10. Convertible Junior Subordinated Debentures
In February 1997, we issued 5% Convertible Junior Subordinated Debentures (the Debentures)
in an aggregate principal amount of $206 million. The Debentures were purchased by McKesson
Financing Trust (the Trust) with proceeds from its issuance of four million shares of preferred
securities to the public and 123,720 common securities to us. The Debentures represented the sole
assets of the Trust and bore interest at an annual rate of 5%, payable quarterly. These preferred
securities of the Trust were convertible into our common stock at the holders option.
16
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
Holders of the preferred securities were entitled to cumulative cash distributions at an
annual rate of 5% of the liquidation amount of $50 per security. Each preferred security was
convertible at the rate of 1.3418 shares of our common stock, subject to adjustment in certain
circumstances. The preferred securities were to be redeemed upon repayment of the Debentures and
were callable by us on or after March 4, 2000, in whole or in part, initially at 103.5% of the
liquidation preference per share, and thereafter at prices declining at 0.5% per annum to 100% of
the liquidation preference on and after March 4, 2007 plus, in each case, accumulated, accrued and
unpaid distributions, if any, to the redemption date.
During the first quarter of 2006, we called for the redemption of the Debentures, which
resulted in the exchange of the preferred securities for 5 million shares of our newly issued
common stock.
11. Pension and Other Postretirement Benefit Plans
Net expense for the Companys defined benefit pension and postretirement plans was $12 million
and $23 million for the second quarter and first half of 2007 compared to $11 million and $22
million for the comparable prior year periods. In July 2006, we made a lump sum cash payment of $7
million from an unfunded U.S. pension plan. In accordance with SFAS No. 88, Employers Accounting
for Settlements and Curtailments of Defined Benefit Pension Plans and for Termination Benefits, a
$2 million settlement charge was recorded in the second quarter of 2007 associated with the
payment.
12. Financial Guarantees and Warranties
Financial Guarantees
We have agreements with certain of our customers financial institutions under which we have
guaranteed the repurchase of inventory (primarily for our Canadian businesses), at a discount, in
the event these customers are unable to meet certain obligations to those financial institutions.
Among other limitations, these inventories must be in resalable condition. We have also guaranteed
loans and the payment of leases for some customers; and we are a secured lender for substantially
all of these guarantees. Customer guarantees range from one to ten years and were primarily
provided to facilitate financing for certain strategic customers. At September 30, 2006, the
maximum amounts of inventory repurchase guarantees and other customer guarantees were approximately
$214 million and $7 million of which a nominal amount has been accrued.
At September 30, 2006, we had commitments of $2 million, primarily consisting of the purchase
of services from our equity-held investments, for which no amounts had been accrued.
In addition, our banks and insurance companies have issued $105 million of standby letters of
credit and surety bonds on our behalf in order to meet the security requirements for statutory
licenses and permits, court and fiduciary obligations, and our workers compensation and automotive
liability programs.
Our software license agreements generally include certain provisions for indemnifying
customers against liabilities if our software products infringe a third partys intellectual
property rights. To date, we have not incurred any material costs as a result of such
indemnification agreements and have not accrued any liabilities related to such obligations.
In conjunction with certain transactions, primarily divestitures, we may provide routine
indemnification agreements (such as retention of previously existing environmental, tax and
employee liabilities) whose terms vary in duration and often are not explicitly defined. Where
appropriate, obligations for such indemnifications are recorded as liabilities. Because the
amounts of these indemnification obligations often are not explicitly stated, the overall maximum
amount of these commitments cannot be reasonably estimated. Other than obligations recorded as
liabilities at the time of divestiture, we have historically not made significant payments as a
result of these indemnification provisions.
17
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
Warranties
In the normal course of business, we provide certain warranties and indemnification protection
for our products and services. For example, we provide warranties that the pharmaceutical and
medical-surgical products we distribute are in compliance with the Food, Drug and Cosmetic Act and
other applicable laws and regulations. We have received the same warranties from our suppliers,
who customarily are the manufacturers of the products. In addition, we have indemnity obligations
to our customers for these products, which have also been provided to us from our suppliers, either
through express agreement or by operation of law.
We also provide warranties regarding the performance of software and automation products we
sell. Our liability under these warranties is to bring the product into compliance with previously
agreed upon specifications. For software products, this may result in additional project costs
which are reflected in our estimates used for the percentage-of-completion method of accounting for
software installation services within these contracts. In addition, most of our customers who
purchase our software and automation products also purchase annual maintenance agreements. Revenue
from these maintenance agreements is recognized on a straight-line basis over the contract period
and the cost of servicing product warranties is charged to expense when claims become estimable.
Accrued warranty costs were not material to the condensed consolidated balance sheets.
13. Contract Settlement
During the second quarter of 2007, we entered into an agreement (the Settlement Agreement)
that settled a patent infringement litigation brought by us against TriZetto Group, Inc.
(TriZetto) and filed on September 13, 2004, McKesson Information Solutions LLC v. The TriZetto Group, Inc. (No. 04-1258-SLR). In the lawsuit, we alleged that sales of clinical editing functionality included in
TriZettos Facets®, QicLinkTM and ClaimFacts® software products infringed one of our patents. As
part of the Settlement Agreement, TriZetto will pay us a one-time royalty fee of $15 million
(payable in two equal installments in October 2006 and September 2007) for a license for
the relevant patent that covers past and future use of TriZetto products and services by all of
their existing customers. TriZetto will continue to include its clinical editing functionality in
versions of Facets® sold to new health plan customers with 100,000 or fewer members and in versions
of QicLinkTM sold to any new customers. TriZetto has also agreed to pay us a royalty fee of 5% of
the net licensing revenue received from new sales of Facets® and QicLinkTM containing its clinical
editing functionality. Additionally, as part of the Settlement Agreement, TriZetto will no longer
include its clinical editing functionality in versions of Facets® sold to new customers with more
than 100,000 members, beginning November 1, 2006. In these cases, new customers may choose their
clinical editing solution from available third-party providers, including McKesson. The Company
expects to amortize the $15 million settlement over the four-year term of the contract, commencing
in the third quarter of 2007.
14. Other Commitments and Contingent Liabilities
I. Securities Litigation
In our annual report on Form 10-K for the year ended March 31, 2006 and in our Form 10-Q for
the quarter ended June 30, 2006, we reported on numerous legal proceedings, including those arising
out of our 1999 announcement of accounting improprieties at HBO & Company (HBOC), now known as
McKesson Information Solutions LLC (the Securities Litigation). Although most of the Securities
Litigation matters have been resolved, as reported previously, certain matters remain pending.
Significant developments in the Securities Litigation and significant events involving other
litigation and claims since the dates of those reports are as follows:
As previously reported, in March 2006, we reached an agreement to settle all claims brought
under the Employee Retirement Income Security Act of 1974 (ERISA) on behalf of a class of certain
participants in the McKesson Profit-Sharing Investment Plan, In re McKesson HBOC, Inc. ERISA
Litigation, (No. C-00-20030 RMW). Such settlement called for the payment of $19 million, plus certain accrued
interest, minus certain costs and expenses such as plaintiffs attorneys fees. On September 1,
2006, the Honorable Ronald M. Whyte entered an order granting final approval to the proposed
settlement. The net cash proceeds of the settlement were distributed in October 2006. The
order of final approval, and the expiration of the time in which an appeal could have been taken
from that order, concludes this matter.
On September 22, 2006, in the previously disclosed actions brought by the Company against
Arthur Andersen LLP (Andersen), McKesson Corporation et al. v Andersen et al., (No. 05-04020 RMW)
and by Andersen against the Company, Andersen v. McKesson Corporation et al., (No. C-06-02035-RMW),
a hearing was conducted on the motions of the Company to dismiss Andersens complaint, and
Andersens motion to dismiss the Companys complaint. The court has not yet ruled on either of
those motions.
In 2005, as previously reported, we recorded a $1,200 million pre-tax ($810 million after-tax)
charge with respect to the Companys Securities Litigation. The charge consisted of $960 million
for the previously reported action in the Northern District of California captioned, In re McKesson
HBOC, Inc. Securities Litigation, (No. C-99-20743 RMW) (the Consolidated Action) and $240 million
for other Securities Litigation proceedings. During 2006, we settled many of the other Securities
Litigation proceedings and paid $243 million pursuant to those settlements. Based on the payments
made in the Consolidated Action and the other Securities Litigation proceedings, settlements
reached in certain of the other Securities Litigation proceedings and our assessment of the
remaining cases, the estimated accrual was increased by net pre-tax charges of $52 million in the
first quarter of 2006 and $45 million for fiscal 2006. Additionally, on February 24, 2006, the
Court gave final approval to the settlement of the Consolidated Action, and as a result, we paid
approximately $960 million into an escrow account established by the lead plaintiff in connection
with the settlement of the Consolidated Action. As of March 31, 2006,
18
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
the Securities Litigation accrual was $1,014 million. The timing of any distribution of
escrowed funds is uncertain in that it is conditioned on completion of the class claims
administration process and also, the Company believes, on the final resolution of the pending Bear
Stearns & Co. appeal.
During the second quarter of 2007, our Securities Litigation accrual was decreased by a net
pre-tax credit of $6 million representing the settlement of the ERISA claims as described above and
a reassessment of another case. The Securities Litigation accrual also reflects a $6 million cash
payment made in 2007 in connection with a settlement. As of September 30, 2006, the Securities
Litigation accrual was $1,002 million. Additionally, as of September 30, 2006, amounts in escrow
increased by $19 million to $981 million primarily reflecting cash transferred for the settlement
of the ERISA claims. We believe our Securities Litigation reserves are adequate to address our
remaining potential exposure with respect to all of the Securities Litigation matters. However, in
view of the number of remaining cases, the uncertainties of the timing and outcome of this type of
litigation, and the substantial amounts involved, it is possible that the ultimate costs of these
matters could impact our earnings, either negatively or positively, in the quarter of their
resolution. We do not believe that the resolution of these matters will have a material adverse
effect on our results of operations, liquidity or financial position taken as a whole.
II. Other Litigation and Claims
As previously reported, a civil class action complaint was filed against the Company in the
United States District Court, District of Massachusetts, New England Carpenters Health Benefits
Fund et al., v. First DataBank, Inc. and McKesson Corporation, (Civil Action No. 05-11148), based
on allegations that the Company, in concert with co-defendant First DataBank, Inc. (FDB), took
certain actions to increase the Average Wholesale Prices (AWPs) of certain branded drugs in
violation of the federal Racketeer Influenced and Corrupt Organizations Act and in violation of
other statutory and common law requirements. On October 4, 2006, the plaintiffs and co-defendant
FDB announced a proposed settlement, as to FDB only, which calls for downward adjustments to
certain FDB published AWPs, a prohibition against all future changes to such AWPs and a prescribed
timetable for the cessation of all publication of AWPs by FDB. On October 24, 2006, the Court
heard plaintiffs petition seeking preliminary approval of the proposed settlement, establishment
of a schedule for objections to the settlement, and requesting a hearing date for the Court to
consider final approval of the settlement. The Court did not on that date grant preliminary
approval of the settlement and did not set a date for a hearing on final approval of the
settlement. The Court did order plaintiffs to seek certain amendments to the complaint as a
prerequisite to any ruling on plaintiffs request for preliminary approval of the settlement. The
schedule regarding the proposed settlement, including dates by which the settlement might be
preliminarily or finally approved, is uncertain at this time. However, there has been no change to
the previously scheduled April 12, 2007, hearing date for consideration of the plaintiffs motion
for class certification, at which hearing the Companys objections to class certification will be
heard.
As indicated in our previous periodic reports, the health care industry is highly regulated,
and government agencies continue to increase their scrutiny over certain practices affecting
government programs. From time to time, the Company receives subpoenas or requests for information
from various government agencies. The Company generally responds to such subpoenas and requests in
a cooperative, thorough and timely manner. These
19
McKESSON CORPORATION
FINANCIAL NOTES (Continued)
(Unaudited)
responses sometimes require considerable time and effort, and can result in considerable costs
being incurred by the Company.
15. Stockholders Equity
Comprehensive income is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
September 30, |
|
September 30, |
(In millions) |
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
Net income |
|
$ |
229 |
|
|
$ |
167 |
|
|
$ |
413 |
|
|
$ |
338 |
|
Foreign currency
translation adjustments
and other |
|
|
|
|
|
|
28 |
|
|
|
39 |
|
|
|
19 |
|
|
|
|
Comprehensive income |
|
$ |
229 |
|
|
$ |
195 |
|
|
$ |
452 |
|
|
$ |
357 |
|
|
The Companys Board of Directors (the Board) approved share repurchase plans in October
2003, August 2005, December 2005 and January 2006 which permitted the Company to repurchase up to a
total of $1 billion ($250 million per plan) of the Companys common stock. Under these plans, we
repurchased 19 million shares for $958 million during 2006 and as of March 31, 2006, less than $1
million of these plans remained available for future repurchases.
In April and July 2006, the Board approved share repurchase plans which permitted the Company
to repurchase up to an additional $1 billion ($500 million per plan) of the Companys common stock.
In the second quarter and the first half of 2007, we repurchased a total of 7 million and 13
million shares for $372 million and $656 million, and $345 million remains available for future
repurchases as of September 30, 2006. Repurchased shares will be used to support our stock-based
employee compensation plans and for other general corporate purposes. Stock repurchases may be
made from time to time in open market or private transactions.
As previously discussed, during the first quarter of 2006, we called for the redemption of the
Debentures, which resulted in the exchange of the preferred securities for 5 million shares of our
newly issued common stock.
16. Segment Information
Our operating segments consist of Pharmaceutical Solutions, Medical-Surgical Solutions and
Provider Technologies. We evaluate the performance of our operating segments based on operating
profit before interest expense, income taxes and results from discontinued operations. Our
Corporate segment includes expenses associated with Corporate functions and projects, certain
employee benefits, and the results of certain joint venture investments. Corporate expenses are
allocated to the operating segments to the extent that these items can be directly attributable to
the segment.
The Pharmaceutical Solutions segment distributes ethical and proprietary drugs, and
health and beauty care products throughout North America. This segment also provides medical
management and specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers,
patient and other services for payors, software and consulting and outsourcing services to
pharmacies, and, through its investment in Parata, sells automated pharmaceutical dispensing
systems for retail pharmacies.
The Medical-Surgical Solutions segment distributes medical-surgical supplies, first-aid
products and equipment, and provides logistics and other services within the United States and
Canada.
The Provider Technologies segment delivers enterprise-wide patient care, clinical, financial,
supply chain, managed care and strategic management software solutions, automated pharmaceutical
dispensing systems for hospitals, as well as outsourcing and other services to healthcare
organizations throughout North America, the United Kingdom and other European countries.
20
McKESSON CORPORATION
FINANCIAL NOTES (Concluded)
(Unaudited)
Financial information relating to our segments is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
September 30, |
|
September 30, |
(In millions) |
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
$ |
21,366 |
|
|
$ |
20,385 |
|
|
$ |
43,688 |
|
|
$ |
40,258 |
|
Medical-Surgical Solutions |
|
|
580 |
|
|
|
508 |
|
|
|
1,157 |
|
|
|
985 |
|
Provider Technologies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services |
|
|
311 |
|
|
|
259 |
|
|
|
608 |
|
|
|
513 |
|
Software and software systems |
|
|
93 |
|
|
|
66 |
|
|
|
172 |
|
|
|
128 |
|
Hardware |
|
|
36 |
|
|
|
35 |
|
|
|
76 |
|
|
|
69 |
|
|
|
|
Total Provider Technologies |
|
|
440 |
|
|
|
360 |
|
|
|
856 |
|
|
|
710 |
|
|
|
|
Total |
|
$ |
22,386 |
|
|
$ |
21,253 |
|
|
$ |
45,701 |
|
|
$ |
41,953 |
|
|
|
|
Operating profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions (1) (2) |
|
$ |
324 |
|
|
$ |
252 |
|
|
$ |
617 |
|
|
$ |
554 |
|
Medical-Surgical Solutions |
|
|
23 |
|
|
|
20 |
|
|
|
45 |
|
|
|
41 |
|
Provider Technologies |
|
|
33 |
|
|
|
26 |
|
|
|
68 |
|
|
|
57 |
|
|
|
|
Total |
|
|
380 |
|
|
|
298 |
|
|
|
730 |
|
|
|
652 |
|
Corporate |
|
|
(48 |
) |
|
|
(37 |
) |
|
|
(91 |
) |
|
|
(58 |
) |
Securities Litigation (charge) credit, net |
|
|
6 |
|
|
|
|
|
|
|
6 |
|
|
|
(52 |
) |
Interest Expense |
|
|
(22 |
) |
|
|
(22 |
) |
|
|
(45 |
) |
|
|
(47 |
) |
|
|
|
Income from continuing operations before income taxes |
|
$ |
316 |
|
|
$ |
239 |
|
|
$ |
600 |
|
|
$ |
495 |
|
|
|
|
|
(1) |
|
During the second quarter and first half of 2007 and the first half of 2006, we received
$10 million and $51 million as our share of settlements of antitrust class action lawsuits
brought against drug manufacturers. These settlements were recorded as a credit in cost of
sales within our Pharmaceutical Solutions segment in our condensed consolidated statements of
operations. |
|
(2) |
|
During the first half of 2007, we recorded $21 million of charges within our Pharmaceutical
Solutions segment as a result of our transaction with Parata. Refer to Financial Note 2,
Acquisitions and Investments. |
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
March 31, |
(In millions) |
|
2006 |
|
2006 |
|
Segment assets |
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
$ |
14,149 |
|
|
$ |
13,737 |
|
Medical-Surgical Solutions |
|
|
1,338 |
|
|
|
1,268 |
|
Provider Technologies |
|
|
1,775 |
|
|
|
1,602 |
|
|
|
|
Total |
|
|
17,262 |
|
|
|
16,607 |
|
Corporate |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
2,254 |
|
|
|
2,139 |
|
Other |
|
|
1,963 |
|
|
|
2,215 |
|
|
|
|
Total |
|
$ |
21,479 |
|
|
$ |
20,961 |
|
|
21
McKESSON CORPORATION
FINANCIAL REVIEW
(Unaudited)
Item 2. Managements Discussion and Analysis of Results of Operations and Financial Condition
Financial Overview
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
(In millions, except per share data) |
|
2006 |
|
|
2005 |
|
|
Change |
|
|
2006 |
|
|
2005 |
|
|
Change |
|
|
Revenues |
|
$ |
22,386 |
|
|
$ |
21,253 |
|
|
|
5 |
% |
|
$ |
45,701 |
|
|
$ |
41,953 |
|
|
|
9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Litigation
pre-tax charge (credit),
net |
|
|
(6 |
) |
|
|
|
|
|
NM |
|
|
|
(6 |
) |
|
|
52 |
|
|
NM |
|
Income from Continuing
Operations Before Income
Taxes |
|
|
316 |
|
|
|
239 |
|
|
|
32 |
|
|
|
600 |
|
|
|
495 |
|
|
|
21 |
|
Discontinued Operations, net |
|
|
(58 |
) |
|
|
15 |
|
|
NM |
|
|
|
(58 |
) |
|
|
20 |
|
|
NM |
|
Net Income |
|
|
229 |
|
|
|
167 |
|
|
|
37 |
|
|
|
413 |
|
|
|
338 |
|
|
|
22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Earnings Per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations |
|
$ |
0.94 |
|
|
$ |
0.48 |
|
|
|
96 |
% |
|
$ |
1.54 |
|
|
$ |
1.02 |
|
|
|
51 |
% |
Discontinued Operations |
|
|
(0.19 |
) |
|
|
0.05 |
|
|
NM |
|
|
|
(0.19 |
) |
|
|
0.06 |
|
|
NM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
0.75 |
|
|
$ |
0.53 |
|
|
|
42 |
|
|
$ |
1.35 |
|
|
$ |
1.08 |
|
|
|
25 |
|
|
Revenues for the quarter ended September 30, 2006 grew 5% to $22.4 billion, net income
increased 37% to $229 million and diluted earnings per share increased 42% to $0.75 compared to the
same period a year ago. For the six months ended September 30, 2006, revenue increased 9% to $45.7
billion, net income increased 22% to $413 million and diluted earnings per share increased 25% to
$1.35 compared to the same period a year ago.
Increases in net income and diluted earnings per share primarily reflect higher operating
profit in our Pharmaceutical Solutions segment and a decrease in pre-tax charges relating to our
Securities Litigation. Net income and diluted earnings per share for 2007 were also impacted by an
$83 million credit to our income tax provision relating to the reversal of income tax reserves for
our Securities Litigation. This credit was partially offset by $58 million of after-tax losses
associated with our discontinued operations. On September 30, 2006, we sold our Medical-Surgical
Solutions segments Acute Care business for net cash proceeds of $160 million, subject to post closing
adjustments. Second quarter 2007 financial results for this business were a loss of $67 million,
which includes a $79 million non-tax deductible write-off of goodwill. Financial results for the
Acute Care business have been reclassified as a discontinued operation for all periods presented.
22
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
Results of Operations
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
(In millions) |
|
2006 |
|
|
2005 |
|
|
Change |
|
|
2006 |
|
|
2005 |
|
|
Change |
|
|
Pharmaceutical Solutions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Healthcare direct
distribution &
services |
|
$ |
13,232 |
|
|
$ |
12,719 |
|
|
|
4 |
% |
|
$ |
26,710 |
|
|
$ |
25,027 |
|
|
|
7 |
% |
U.S. Healthcare sales
to customers
warehouses |
|
|
6,483 |
|
|
|
6,199 |
|
|
|
5 |
|
|
|
13,577 |
|
|
|
12,277 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal |
|
|
19,715 |
|
|
|
18,918 |
|
|
|
4 |
|
|
|
40,287 |
|
|
|
37,304 |
|
|
|
8 |
|
Canada distribution &
services |
|
|
1,651 |
|
|
|
1,467 |
|
|
|
13 |
|
|
|
3,401 |
|
|
|
2,954 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Pharmaceutical
Solutions |
|
|
21,366 |
|
|
|
20,385 |
|
|
|
5 |
|
|
|
43,688 |
|
|
|
40,258 |
|
|
|
9 |
|
Medical-Surgical Solutions |
|
|
580 |
|
|
|
508 |
|
|
|
14 |
|
|
|
1,157 |
|
|
|
985 |
|
|
|
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provider Technologies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services |
|
|
311 |
|
|
|
259 |
|
|
|
20 |
|
|
|
608 |
|
|
|
513 |
|
|
|
19 |
|
Software and software
systems |
|
|
93 |
|
|
|
66 |
|
|
|
41 |
|
|
|
172 |
|
|
|
128 |
|
|
|
34 |
|
Hardware |
|
|
36 |
|
|
|
35 |
|
|
|
3 |
|
|
|
76 |
|
|
|
69 |
|
|
|
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Provider
Technologies |
|
|
440 |
|
|
|
360 |
|
|
|
22 |
|
|
|
856 |
|
|
|
710 |
|
|
|
21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
$ |
22,386 |
|
|
$ |
21,253 |
|
|
|
5 |
|
|
$ |
45,701 |
|
|
$ |
41,953 |
|
|
|
9 |
|
|
Revenues increased by 5% and 9% to $22.4 billion and $45.7 billion during the quarter and six
months ended September 30, 2006 compared to the same periods a year ago. The increase primarily
reflects growth in our Pharmaceutical Solutions segment, which accounted for over 95% of
consolidated revenues.
U.S. Healthcare pharmaceutical direct distribution and services revenues increased primarily
reflecting market growth rates, expanded agreements with customers and the acquisition of D&K
Healthcare Resources, Inc. (D&K) during the second quarter of 2006, partially offset by the loss
of a large customer. U.S. Healthcare sales to customers warehouses increased primarily as a
result of new and expanded agreements with customers, offset in part by a decrease in volume from a
large customer. Additionally, revenues for our U.S. pharmaceutical distribution business were
negatively impacted by one less sales day in 2007 compared to 2006.
Canadian pharmaceutical distribution revenues increased reflecting favorable foreign exchange
rates and market growth rates. Had the same U.S. and Canadian dollar exchange rates applied in
2007 as in 2006, revenues for the second quarter and first half of 2007 from our Canadian
operations would have increased approximately 5% compared to the same periods a year ago.
Medical-Surgical Solutions segment distribution revenues increased primarily reflecting above
average market growth rates as well as the acquisition of Sterling Medical Services LLC
(Sterling) during the first quarter of 2007. Sterling is based in Moorestown, New Jersey, and is
a national provider and distributor of medical disposable supplies, health management services and
quality management programs to the home care market. Additionally, revenues for the first half of
2007 include an extra week of sales compared to the same period a year ago.
Provider Technologies segment revenues increased reflecting higher sales and implementations
of clinical, imaging, and automation solutions. Growth in this segments revenues was not
materially impacted by business acquisitions.
23
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
Gross Profit:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
(Dollars in millions) |
|
2006 |
|
|
2005 |
|
|
Change |
|
|
2006 |
|
|
2005 |
|
|
Change |
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
$ |
650 |
|
|
$ |
565 |
|
|
|
15 |
% |
|
$ |
1,293 |
|
|
$ |
1,159 |
|
|
|
12 |
% |
Medical-Surgical Solutions |
|
|
166 |
|
|
|
142 |
|
|
|
17 |
|
|
|
331 |
|
|
|
282 |
|
|
|
17 |
|
Provider Technologies |
|
|
208 |
|
|
|
161 |
|
|
|
29 |
|
|
|
396 |
|
|
|
323 |
|
|
|
23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
1,024 |
|
|
$ |
868 |
|
|
|
18 |
|
|
$ |
2,020 |
|
|
$ |
1,764 |
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit Margin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
|
3.04 |
% |
|
|
2.77 |
% |
|
|
27 |
bp |
|
|
2.96 |
% |
|
|
2.88 |
% |
|
|
8 |
bp |
Medical-Surgical Solutions |
|
|
28.62 |
|
|
|
27.95 |
|
|
|
67 |
|
|
|
28.61 |
|
|
|
28.63 |
|
|
|
(2 |
) |
Provider Technologies |
|
|
47.27 |
|
|
|
44.72 |
|
|
|
255 |
|
|
|
46.26 |
|
|
|
45.49 |
|
|
|
77 |
|
Total |
|
|
4.57 |
|
|
|
4.08 |
|
|
|
49 |
|
|
|
4.42 |
|
|
|
4.20 |
|
|
|
22 |
|
|
Gross profit for the second quarter and first half of 2007 increased 18% and 15% to $1,024
million and $2,020 million. As a percentage of revenues, gross profit margin increased 49 basis
points to 4.57% for the second quarter of 2007 and 22 basis points to 4.42% for the first half of
2007. Gross profit margin increased primarily reflecting an increase in our gross profit margins
in our Pharmaceutical Solutions and Provider Technologies segments.
Gross profit margin for our Pharmaceutical Solutions segment increased during the second
quarter of 2007 compared to the same period a year ago, primarily as a result of the benefit of
increased sales of generic drugs with higher margins and the receipt of $10 million of cash
proceeds representing our share of a settlement of an antitrust class action lawsuit. In addition,
gross profit margin for this segment has experienced a stabilization of its U.S. pharmaceutical
distribution business sell and buy side margins in 2007.
Gross profit margin for our Pharmaceutical Solutions segment increased during the first half
of 2007 compared to the same period a year ago, primarily as a result of:
|
|
the benefit of increased sales of generic drugs with higher
margins, and |
|
|
|
a last-in, first-out (LIFO) inventory credit of $20 million in the first half of 2007 compared with $10 million in
the first half of 2006. These LIFO credits reflect our expectation of a LIFO benefit for the full fiscal year. Our
Pharmaceutical Solutions segment uses the LIFO method of accounting for the majority of its inventories, which results
in cost of sales that more closely reflects replacement cost than do other accounting methods, thereby mitigating the
effects of inflation and deflation on gross profit. The practice in the Pharmaceutical Solutions distribution business
is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price
protection, which prevents inventory losses. Price declines on many generic pharmaceutical products in this segment
over the last few years have moderated the effects of inflation in other product categories, which resulted in minimal
overall price changes in those years. |
|
|
|
These increases were partially offset by: |
|
|
|
a decrease in amounts of antitrust settlements. Results for the first half of 2007 and 2006 included $10 million and
$51 million of cash proceeds representing our share of settlements of various antitrust class action lawsuits, |
|
|
|
a decrease associated with a greater proportion of revenues within the segment attributed to sales to customers
warehouses, which have lower gross profit margins relative to other revenues within the segment, and |
24
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
|
|
a $15 million charge pertaining to the writedown of certain abandoned assets within our retail
automation group. During the first half of 2007, we contributed $36 million in cash and $45
million in net assets primarily from our Automated Prescription Systems business to Parata
Systems, LLC (Parata), in exchange for a significant minority interest in Parata. In
connection with the investment, we abandoned certain assets which resulted in a $15 million
charge to cost of sales and we incurred $6 million of other expenses related to the transaction
which were recorded within operating expenses. We did not recognize any additional gains or
losses as a result of this transaction as we believe the fair value of our investment in Parata,
as determined by a third-party valuation, approximates the carrying value of consideration
contributed to Parata. Our investment in Parata is accounted for under the equity method of
accounting within our Pharmaceutical Solutions segment. |
Gross profit margins increased in our Medical-Surgical Solutions segment during the second
quarter of 2007 compared to the same period a year ago primarily reflecting favorable buy side
margins. For the first half of 2007, gross profit margins for this segment approximated that of
the prior comparable period. Provider Technologies segments gross profit margin increased
primarily due to a change in product mix.
Operating Expenses and Other Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
(Dollars in millions) |
|
2006 |
|
|
2005 |
|
|
Change |
|
|
2006 |
|
|
2005 |
|
|
Change |
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
$ |
333 |
|
|
$ |
321 |
|
|
|
4 |
% |
|
$ |
695 |
|
|
$ |
621 |
|
|
|
12 |
% |
Medical-Surgical Solutions |
|
|
144 |
|
|
|
123 |
|
|
|
17 |
|
|
|
287 |
|
|
|
242 |
|
|
|
19 |
|
Provider Technologies |
|
|
177 |
|
|
|
140 |
|
|
|
26 |
|
|
|
333 |
|
|
|
273 |
|
|
|
22 |
|
Corporate |
|
|
70 |
|
|
|
58 |
|
|
|
21 |
|
|
|
133 |
|
|
|
96 |
|
|
|
39 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal |
|
|
724 |
|
|
|
642 |
|
|
|
13 |
|
|
|
1,448 |
|
|
|
1,232 |
|
|
|
18 |
|
Securities Litigation
charge (credit), net |
|
|
(6 |
) |
|
|
|
|
|
NM |
|
|
(6 |
) |
|
|
52 |
|
|
NM |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
718 |
|
|
$ |
642 |
|
|
|
12 |
|
|
$ |
1,442 |
|
|
$ |
1,284 |
|
|
|
12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses as a
Percentage of Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
|
1.56 |
% |
|
|
1.57 |
% |
|
|
(1 |
) bp |
|
|
1.59 |
|
|
|
1.54 |
% |
|
|
5 |
bp |
Medical-Surgical Solutions |
|
|
24.83 |
|
|
|
24.21 |
|
|
|
62 |
|
|
|
24.81 |
|
|
|
24.57 |
|
|
|
24 |
|
Provider Technologies |
|
|
40.23 |
|
|
|
38.89 |
|
|
|
134 |
|
|
|
38.90 |
|
|
|
38.45 |
|
|
|
45 |
|
Total |
|
|
3.21 |
|
|
|
3.02 |
|
|
|
19 |
|
|
|
3.16 |
|
|
|
3.06 |
|
|
|
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
$ |
7 |
|
|
$ |
8 |
|
|
|
(13 |
)% |
|
$ |
19 |
|
|
$ |
16 |
|
|
|
19 |
% |
Medical-Surgical Solutions |
|
|
1 |
|
|
|
1 |
|
|
|
|
|
|
|
1 |
|
|
|
1 |
|
|
|
|
|
Provider Technologies |
|
|
2 |
|
|
|
5 |
|
|
|
(60 |
) |
|
|
5 |
|
|
|
7 |
|
|
|
(29 |
) |
Corporate |
|
|
22 |
|
|
|
21 |
|
|
|
5 |
|
|
|
42 |
|
|
|
38 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
32 |
|
|
$ |
35 |
|
|
|
(9 |
) |
|
$ |
67 |
|
|
$ |
62 |
|
|
|
8 |
|
|
Operating expenses increased 12% to $718 million in the second quarter of 2007 (or 13%
excluding the Securities Litigation credit) to $724 million and for the first half of 2007
increased 12% to $1,442 million (or 18% excluding the Securities Litigation charges and credits to
$1,448 million). As a percentage of revenues, operating expenses increased 19 and 10 basis points
to 3.21% and 3.16% for the second quarter and first half of 2007. Excluding the Securities
Litigation charges and credits, operating expenses as a percentage of revenues increased 21 and 23
basis points to 3.23% and 3.17% for the second quarter and first half of 2007. Operating expense
dollars, excluding the Securities Litigation, increased primarily due to additional costs to
support our sales volume growth, our business acquisitions, and employee compensation costs
associated with the requirement to expense all share-based compensation. Other income decreased
slightly in the second quarter of 2007 and increased slightly in the first half of 2007 compared to
the same periods a year ago.
25
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
During the first quarter of 2007, we adopted Statement of Financial Accounting Standards
(SFAS) No. 123(R), Share-Based Payment, which requires the recognition of expense resulting
from transactions in which we acquire goods and services by issuing our shares, share options, or
other equity instruments. As a result of the implementation, included in our second quarter and
first half 2007 operating expenses, we recorded $16 million and $24 million of pre-tax share-based
compensation expense, or $13 million and $17 million more than the same periods a year ago.
We
now expect share-based compensation charges to approximate $0.10 to
$0.12 per
diluted share, or an increase of $0.02 per diluted shares more than
our previous expectations. These charges are now expected to be
approximately $0.07 to $0.09 per diluted share more than the share-based
compensation expense recognized in our net income in 2006. 2006 net income includes $0.03 per
diluted share of compensation expense associated with restricted stock whose intrinsic value as of
the grant date is being amortized over the vesting period. Our assessments of estimated
compensation charges are affected by our stock price as well as assumptions regarding a number of
complex and subjective variables and the related tax impact. These variables include, but are not
limited to, the volatility of our stock price, employee stock option exercise behaviors, timing,
level and types of our grants of annual share-based awards, and the attainment of performance
goals. As a result, the actual share-based compensation expense in 2007 may differ from the
Companys current estimate.
Refer to Financial Notes 1 and 4, Significant Accounting Policies and Share-Based Payment,
to the accompanying condensed consolidated financial statements for further discussions regarding
our share-based compensation.
Segment Operating Profit and Corporate Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
(Dollars in millions) |
|
2006 |
|
|
2005 |
|
|
Change |
|
|
2006 |
|
|
2005 |
|
|
Change |
|
|
Segment Operating Profit(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions
(2) |
|
$ |
324 |
|
|
$ |
252 |
|
|
|
29 |
% |
|
$ |
617 |
|
|
$ |
554 |
|
|
|
11 |
% |
Medical-Surgical Solutions |
|
|
23 |
|
|
|
20 |
|
|
|
15 |
|
|
|
45 |
|
|
|
41 |
|
|
|
10 |
|
Provider Technologies |
|
|
33 |
|
|
|
26 |
|
|
|
27 |
|
|
|
68 |
|
|
|
57 |
|
|
|
19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal |
|
|
380 |
|
|
|
298 |
|
|
|
28 |
|
|
|
730 |
|
|
|
652 |
|
|
|
12 |
|
Corporate Expenses, net |
|
|
(48 |
) |
|
|
(37 |
) |
|
|
30 |
|
|
|
(91 |
) |
|
|
(58 |
) |
|
|
57 |
|
Securities Litigation (charge) credit, net |
|
|
6 |
|
|
|
|
|
|
NM |
|
|
|
6 |
|
|
|
(52 |
) |
|
NM |
Interest Expense |
|
|
(22 |
) |
|
|
(22 |
) |
|
|
|
|
|
|
(45 |
) |
|
|
(47 |
) |
|
|
(4 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Continuing Operations, Before
Income Taxes |
|
$ |
316 |
|
|
$ |
239 |
|
|
|
32 |
|
|
$ |
600 |
|
|
$ |
495 |
|
|
|
21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Operating Profit Margin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
|
1.52 |
% |
|
|
1.24 |
% |
|
|
28 |
bp |
|
|
1.41 |
% |
|
|
1.38 |
% |
|
|
3 |
bp |
Medical-Surgical Solutions |
|
|
3.97 |
|
|
|
3.94 |
|
|
|
3 |
|
|
|
3.89 |
|
|
|
4.16 |
|
|
|
(27 |
) |
Provider Technologies |
|
|
7.50 |
|
|
|
7.22 |
|
|
|
28 |
|
|
|
7.94 |
|
|
|
8.03 |
|
|
|
(9 |
) |
|
|
|
|
(1) |
|
Segment operating profit includes gross profit, net of operating expenses plus other income
for our three business segments. |
|
(2) |
|
During the second quarter and first half of 2007 and the first half of 2006, we received $10
million and $51 million as our share of settlements of antitrust class action lawsuits brought
against drug manufacturers. |
Operating profit as a percentage of revenues increased in our Pharmaceutical Solutions
segment largely as a result of an increase in the segments gross profit margin. Results for the
second quarter of 2007 also benefited from a leveraging of the segments operating expenses as well
as the timing of certain expenses. Operating expenses increased in the first half of 2007
primarily reflecting additional costs to support the segments
sales volume growth, our D&K
acquisitions, and employee share-based compensation costs.
26
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
Medical-Surgical Solutions segments operating profit as a percentage of revenues for the
second quarter of 2007 approximated that of the prior year comparable period and decreased during
the first half of 2007. Operating profit as a percentage of revenues for the first half of 2007
decreased primarily as operating expenses as a percentage of revenues increased. Operating expenses for the segment increased primarily reflecting
additional costs to support the segments sales volume growth and the acquisition of
Sterling. As part of this segments divestiture of its Acute
Care business, we expect to incur
restructuring charges of approximately $5 million in the latter part of 2007 in order to align the
segments remaining operations.
Provider Technologies segments operating profit as a percentage of revenues increased
primarily reflecting an increase in gross profit margin, offset in part by an increase in operating
expenses as a percentage of revenues. Operating expenses for the segment increased primarily
reflecting investments in research and development activities and sales functions to support the
segments revenue growth, the segments business acquisitions, increases in employee share-based
compensation costs and bad debt expense. Operating expenses for 2006 benefited from favorable
adjustments to the segments bad debt expense. Partially offsetting these increases, during the
second quarter of 2006, the segment wrote off $3 million of acquired in-process research and
development costs resulting from the Medcon, Ltd. (Medcon) acquisition. Additionally, operating
expenses for the first half of 2007 include $6 million of restructuring charges as a result of a
plan intended to reallocate product development and marketing resources.
Corporate expenses, net of other income, increased during the second quarter of 2007 primarily
reflecting additional costs incurred to support various initiatives, an increase in employee
share-based compensation costs and a pension settlement expense. These increases were partially
offset by a decrease in charges for loans made to former employees. Corporate expenses, net of
other income, increased during the first half of 2007 primarily reflecting additional costs
incurred to support various initiatives, as well as increases associated with charges for loans
made to former employees and employee share-based compensation costs. These unfavorable variances
were partially offset by a decrease in legal costs associated with our Securities Litigation and an
increase in interest income. Corporate expenses for the first half of 2006 also benefited from a
change in estimate for certain compensation and benefits plans.
Securities Litigation Charges, Net: In 2005, we recorded a $1,200 million pre-tax ($810
million after-tax) charge with respect to the Companys Securities Litigation. The charge
consisted of $960 million for the previously reported action in the Northern District of California
captioned, In re McKesson HBOC, Inc. Securities Litigation, (No. C-99-20743 RMW) (the Consolidated
Action) and $240 million for other Securities Litigation proceedings. During 2006, we settled
many of the other Securities Litigation proceedings and paid $243 million pursuant to those
settlements. Based on the payments made in the Consolidated Action and the other Securities
Litigation proceedings, settlements reached in certain of the other Securities Litigation
proceedings and our assessment of the remaining cases, the estimated accrual was increased by
pre-tax charges of $52 million in the first quarter of 2006 and $45 million for fiscal 2006.
Additionally, on February 24, 2006, the Court gave final approval to the settlement of the
Consolidated Action, and as a result, we paid approximately $960 million into an escrow account
established by the lead plaintiff in connection with the settlement of the Consolidated Action. As
of March 31, 2006, the Securities Litigation accrual was $1,014 million. The timing of any
distribution of escrowed funds is uncertain in that it is conditioned on completion of the class
claims administration process and also, the Company believes, on the final resolution of the
pending Bear Stearns & Co. appeal.
As previously reported, in March 2006, we reached an agreement to settle all claims brought
under the Employee Retirement Income Security Act of 1974 (ERISA) on behalf of a class of certain
participants in the McKesson Profit-Sharing Investment Plan, In re McKesson HBOC, Inc. ERISA
Litigation, (No. C-00-20030 RMW). Such settlement called for
the payment of $19 million, plus certain accrued
interest, minus certain costs and expenses such as plaintiffs attorneys fees. On September 1,
2006, the Honorable Ronald M. Whyte entered an order granting final approval to the proposed
settlement. The net cash proceeds of the settlement were distributed
in October 2006. That
order of final approval, and the expiration of the time in which an appeal could have been taken
from that order, concludes this matter.
27
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
During the second quarter of 2007, our Securities Litigation accrual was decreased by a net
pre-tax credit of $6 million representing the settlement of the ERISA claims as described above and
a reassessment of another case. The Securities Litigation accrual also reflects a $6 million cash
payment made in 2007 in connection with a settlement. As of September 30, 2006, the Securities
Litigation accrual was $1,002 million. Additionally, as of September 30, 2006, amounts in escrow
increased by $19 million to $981 million primarily reflecting cash transferred for the settlement
of the ERISA claims. We believe our Securities Litigation reserves are adequate to address our
remaining potential exposure with respect to all of the Securities Litigation matters. However, in
view of the number of remaining cases, the uncertainties of the timing and outcome of this type of
litigation, and the substantial amounts involved, it is possible that the ultimate costs of these
matters could impact our earnings, either negatively or positively, in the quarter of their
resolution. We do not believe that the resolution of these matters will have a material adverse
effect on our results of operations, liquidity or financial position taken as a whole.
Interest Expense: Interest expense for 2007 approximated that of the prior year comparable
periods.
Income Taxes: The Companys reported income tax rates for the quarters ended September 30,
2006 and 2005 were 9.2% and 36.4%, and 21.5% and 35.8% for the first
halves of 2007 and 2006. During
the second quarter of 2007, we recorded a credit to income tax expense of $83 million which
primarily pertains to our receipt of a private letter ruling from the U.S. Internal Revenue Service
(IRS) holding that our payment of approximately $960 million to settle our Securities Litigation
Consolidated Action is fully tax-deductible. We previously established tax reserves to reflect the
lack of certainty regarding the tax deductibility of settlement amounts paid in the Consolidated
Action and related litigation.
Discontinued Operations:
Results from discontinued operations were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
September 30, |
|
September 30, |
(In millions) |
|
2006 |
|
2005 |
|
2006 |
|
2005 |
|
Discontinued
operations, net of
taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acute Care |
|
$ |
(67 |
) |
|
$ |
2 |
|
|
$ |
(67 |
) |
|
$ |
6 |
|
PBI |
|
|
5 |
|
|
|
|
|
|
|
5 |
|
|
|
|
|
BioServices |
|
|
|
|
|
|
13 |
|
|
|
|
|
|
|
14 |
|
Other |
|
|
4 |
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
|
Total |
|
$ |
(58 |
) |
|
$ |
15 |
|
|
$ |
(58 |
) |
|
$ |
20 |
|
|
In July 2006, we signed an agreement to sell our Medical-Surgical Solutions segments Acute
Care supply business to Owens & Minor, Inc. (OMI) for net cash proceeds of approximately $160 million,
subject to certain adjustments. This transaction closed on September 30, 2006. In accordance with
SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the financial
results of this business are classified as a discontinued operation for all periods presented in
the accompanying condensed consolidated financial statements. Revenues associated with the Acute
Care business were $274 million and $260 million for the second quarters of 2007 and 2006, and $573
million and $528 million for the first halves of 2007 and 2006. Financial results for this
discontinued operation include an after-tax loss of $67 million, which primarily consists of an
after-tax loss of $61 million for the business disposition and $6 million of after-tax losses
associated with operations, other asset impairment charges and employee severance costs. The
after-tax loss of $61 million for the business disposition includes a $79 million non-tax
deductible write-off of goodwill, as further described below.
28
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
In connection with this divestiture, we allocated a portion of our Medical-Surgical Solutions
segments goodwill to the Acute Care business as required by SFAS No. 142, Goodwill and Other
Intangible Assets. The allocation was based on the relative fair values of the Acute Care
business and the continuing businesses that are being retained by the Company. The fair value of
the Acute Care business was determined based on the net cash proceeds resulting from the divestiture and
the fair value of the continuing businesses was determined by a third-party valuation. As a result, we
allocated $79 million of the segments goodwill to the Acute Care business.
Additionally, as part of the divestiture, we entered into a transition services agreement
(TSA) with OMI under which we will continue to provide certain services to the Acute Care
business during a transition period of approximately nine months. We also anticipate incurring
approximately $6 million of pre-tax employee severance charges over the transition period. These
charges, as well as the financial results from the TSA, will be recorded as part of discontinued
operations. The continuing cash flows generated from the TSA are not anticipated to be material to
our condensed consolidated financial statements.
In the second quarter of 2007, we also sold a wholly-owned subsidiary, Pharmaceutical Buyers Inc. (PBI), for
net cash proceeds of $10 million. The divestiture resulted in an after-tax gain of $5 million resulting
from the tax basis of the subsidiary exceeding its carrying value. Financial results of this
business, which were previously included in our Pharmaceutical Solutions segment, have been
presented as a discontinued operation for all periods presented in the accompanying condensed
consolidated financial statements. These results were not material to our condensed consolidated
financial statements.
Results for discontinued operations for 2007 also include an after-tax gain of $4 million
associated with the collection of a note receivable from a business sold in 2003.
In the second quarter of 2006, we sold our wholly-owned subsidiary, McKesson BioServices
Corporation (BioServices), for net cash proceeds of $63 million. The divestiture resulted in an
after-tax gain of $13 million. Financial results for this business, which were previously included
in our Pharmaceutical Solutions segment, have been presented as a discontinued operation for all
periods presented in the accompanying condensed consolidated financial statements. These results
were not material to our condensed consolidated financial statements.
Refer to Financial Note 3, Discontinued Operations, to the accompanying condensed
consolidated financial statements for further discussions regarding our divestitures.
Net Income: Net income was $229 million and $167 million for the second quarters of 2007 and
2006, or $0.75 and $0.53 per diluted share. Net income was $413 million and $338 million for the
first halves of 2007 and 2006, or $1.35 and $1.08 per diluted share. Net income for the second
quarter and first half of 2007 includes an $87 million after-tax credit, or $0.28 and $0.29 per
diluted share, relating to our Securities Litigation. Net income for the first half of 2006
includes a $35 million after-tax Securities Litigation charge, or ($0.11) per diluted share. Net
income for 2007 also includes $58 million of after-tax losses for our discontinued operations
primarily pertaining to the disposition of our Acute Care business.
29
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
A reconciliation between our net income per share reported in conformity
with generally accepted accounting principles in the United States of America (U.S. GAAP) purposes and our
earnings per diluted share, excluding charges for the Securities Litigation for the second quarters
and first halves of 2007 and 2006 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
|
Six Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
(In millions except per share amounts) |
|
2006 |
|
|
2005 |
|
|
2006 |
|
|
2005 |
|
|
Net income, as reported |
|
$ |
229 |
|
|
$ |
167 |
|
|
$ |
413 |
|
|
$ |
338 |
|
Exclude: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Litigation
charge (credit), net |
|
|
(6 |
) |
|
|
|
|
|
|
(6 |
) |
|
|
52 |
|
Income taxes |
|
|
2 |
|
|
|
|
|
|
|
2 |
|
|
|
(17 |
) |
Income tax reserve reversals |
|
|
(83 |
) |
|
|
|
|
|
|
(83 |
) |
|
|
|
|
|
|
|
Securities Litigation
charge (credit), net of tax |
|
|
(87 |
) |
|
|
|
|
|
|
(87 |
) |
|
|
35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, excluding
Securities Litigation charges |
|
$ |
142 |
|
|
$ |
167 |
|
|
$ |
326 |
|
|
$ |
373 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per common
share, as reported
(1) |
|
$ |
0.75 |
|
|
$ |
0.53 |
|
|
$ |
1.35 |
|
|
$ |
1.08 |
|
Diluted earnings per common
share, excluding Securities
Litigation charge (credit)
(1) |
|
$ |
0.47 |
|
|
$ |
0.53 |
|
|
$ |
1.06 |
|
|
$ |
1.19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares on which diluted
earnings per common share,
excluding the Securities
Litigation charge (credit),
were based |
|
|
305 |
|
|
|
316 |
|
|
|
307 |
|
|
|
315 |
|
|
|
|
|
(1) |
|
For the six months ended September 30, 2005, interest expense, net of related income taxes,
of $1 million, has been added to net income, excluding the Securities Litigation net charges,
for purpose of calculating diluted earnings per share. This calculation also includes the
impact of dilutive securities (stock options, convertible junior subordinated debentures and
restricted stock). |
These pro forma amounts are non-GAAP financial measures. We use these measures
internally and consider these results to be useful to investors as they provide the most relevant
benchmarks of core operating performance.
Weighted Average Diluted Shares Outstanding: Diluted earnings per share were calculated based
on an average number of diluted shares outstanding of 305 million and 316 million for the second
quarters of 2007 and 2006 and 307 million and 315 million for the six months ended September 30,
2006 and 2005. The decrease in the number of weighted average diluted shares outstanding reflects
a decrease in the number of common shares outstanding as a result of repurchased stock, partially
offset by exercised stock options, as well as an increase in the common stock equivalents from
stock options due to the increase in the Companys common stock price.
Business Acquisitions
In the first half of 2007, we acquired the following three entities for a total cost of $91
million, which was paid in cash:
|
|
Sterling, based in Moorestown, New Jersey, a national provider and
distributor of medical disposable supplies, health management
services and quality management programs to the home care market.
Financial results for Sterling are included in our
Medical-Surgical Solutions segment;
|
30
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
|
|
HealthCom Partners LLC (HealthCom), based in Mt. Prospect,
Illinois, a leading provider of patient billing solutions designed
to simplify and enhance healthcare providers financial
interactions with their patients; and |
|
|
|
RelayHealth Corporation (RelayHealth), based in Emeryville,
California, a provider of secure online healthcare communication
services linking patients, healthcare professionals, payors and
pharmacies. Financial results for HealthCom and RelayHealth are
included in our Provider Technologies segment. |
Goodwill recognized in these transactions amounted to $60 million.
In addition, in the first quarter of 2007, we contributed $36 million in cash and $45 million
in net assets primarily from our Automated Prescription Systems business to Parata, in exchange for
a significant minority interest in Parata. In connection with the investment, we abandoned certain
assets which resulted in a $15 million charge to cost of sales and we incurred $6 million of other
expenses related to the transaction which were recorded within operating expenses. We did not
recognize any additional gains or losses as a result of this transaction as we believe the fair
value of our investment in Parata, as determined by a third-party valuation, approximates the
carrying value of consideration contributed to Parata. Our investment in Parata is accounted for
under the equity method of accounting within our Pharmaceutical Solutions segment.
In 2006, we made the following acquisitions:
|
|
In the second quarter of 2006, we acquired all of the issued and
outstanding stock of D&K of St. Louis, Missouri, for an aggregate
cash purchase price of $479 million, including the assumption of
D&Ks debt. D&K is primarily a wholesale distributor of branded
and generic pharmaceuticals and over-the-counter health and beauty
products to independent and regional pharmacies, primarily in the
Midwest. Approximately $158 million of the purchase price has
been assigned to goodwill. Included in the purchase price were
acquired identifiable intangibles of $43 million primarily
representing customer lists and not-to-compete covenants which
have an estimated weighted-average useful life of nine years.
Financial results for D&K are included in our Pharmaceutical
Solutions segment. |
|
|
|
Also in the second quarter of 2006, we acquired all of the issued
and outstanding shares of Medcon, an Israeli company, for an
aggregate purchase price of $82 million. Medcon provides
web-based cardiac image and information management services to
healthcare providers. Approximately $60 million of the purchase
price was assigned to goodwill and $20 million was assigned to
intangibles which represent technology assets and customer lists
which have an estimated weighted-average useful life of four
years. Financial results for Medcon are included in our Provider
Technologies segment. |
During the last two years, we also completed a number of other acquisitions and investments
within all three of our operating segments. Financial results for our business acquisitions have
been included in our consolidated financial statements since their respective acquisition dates.
Purchase prices for our business acquisitions have been allocated based on estimated fair values at
the date of acquisition and, for certain recent acquisitions, may be subject to change. Goodwill
recognized for our business acquisitions is not expected to be deductible for tax purposes. Pro
forma results of operations for our business acquisitions have not been presented because the
effects were not material to the consolidated financial statements on either an individual or an
aggregate basis.
Refer to Financial Note 2, Acquisitions and Investments, to the accompanying condensed
consolidated financial statements for further discussions regarding our business acquisitions.
31
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
Segment Reclassifications
During the second quarter of 2007, we sold our Medical-Surgical Solutions segments Acute Care
business and a small business within our Pharmaceutical Solutions segment. Financial results for
these businesses have been reclassified as discontinued operations. Historical financial results
for 2006 and the first quarter of 2007 for our segments continuing operations are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 |
|
2007 |
|
|
Quarter |
|
Quarter |
|
Quarter |
|
Quarter |
|
Year |
|
Quarter |
|
|
ended |
|
ended |
|
ended |
|
ended |
|
ended |
|
ended |
|
|
June 30, |
|
September |
|
December |
|
March 31, |
|
March 31, |
|
June 30, |
(Dollars in millions) |
|
2005 |
|
30, 2005 |
|
31, 2005 |
|
2006 |
|
2006 |
|
2006 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical Solutions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Healthcare
direct distribution &
services |
|
$ |
12,308 |
|
|
$ |
12,719 |
|
|
$ |
13,242 |
|
|
$ |
13,763 |
|
|
$ |
52,032 |
|
|
$ |
13,477 |
|
U.S.
Healthcare sales
to customers
warehouses |
|
|
6,078 |
|
|
|
6,199 |
|
|
|
6,523 |
|
|
|
6,662 |
|
|
|
25,462 |
|
|
|
7,094 |
|
|
|
|
Subtotal |
|
|
18,386 |
|
|
|
18,918 |
|
|
|
19,765 |
|
|
|
20,425 |
|
|
|
77,494 |
|
|
|
20,571 |
|
Canada direct
distribution &
services |
|
|
1,487 |
|
|
|
1,467 |
|
|
|
1,530 |
|
|
|
1,426 |
|
|
|
5,910 |
|
|
|
1,750 |
|
|
|
|
Total
Pharmaceutical
Solutions |
|
|
19,873 |
|
|
|
20,385 |
|
|
|
21,295 |
|
|
|
21,851 |
|
|
|
83,404 |
|
|
|
22,321 |
|
|
|
|
Medical-Surgical
Solutions |
|
|
477 |
|
|
|
508 |
|
|
|
544 |
|
|
|
508 |
|
|
|
2,037 |
|
|
|
577 |
|
|
|
|
|
Provider Technologies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services |
|
|
62 |
|
|
|
66 |
|
|
|
90 |
|
|
|
104 |
|
|
|
322 |
|
|
|
79 |
|
Software and software
systems |
|
|
254 |
|
|
|
259 |
|
|
|
269 |
|
|
|
287 |
|
|
|
1,069 |
|
|
|
297 |
|
Hardware |
|
|
34 |
|
|
|
35 |
|
|
|
42 |
|
|
|
40 |
|
|
|
151 |
|
|
|
41 |
|
|
|
|
Total Provider
Technologies |
|
|
350 |
|
|
|
360 |
|
|
|
401 |
|
|
|
431 |
|
|
|
1,542 |
|
|
|
417 |
|
|
|
|
Total Revenues |
|
$ |
20,700 |
|
|
$ |
21,253 |
|
|
$ |
22,240 |
|
|
$ |
22,790 |
|
|
$ |
86,983 |
|
|
$ |
23,315 |
|
|
|
|
Segment Operating Profit: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
Solutions |
|
$ |
302 |
|
|
$ |
252 |
|
|
$ |
305 |
|
|
$ |
352 |
|
|
$ |
1,211 |
|
|
$ |
292 |
|
Medical-Surgical
Solutions |
|
|
21 |
|
|
|
20 |
|
|
|
26 |
|
|
|
16 |
|
|
|
83 |
|
|
|
22 |
|
Provider Technologies |
|
|
31 |
|
|
|
26 |
|
|
|
38 |
|
|
|
48 |
|
|
|
143 |
|
|
|
35 |
|
|
|
|
Operating
Profit |
|
|
354 |
|
|
|
298 |
|
|
|
369 |
|
|
|
416 |
|
|
|
1,437 |
|
|
|
349 |
|
Interest Expense |
|
|
(21 |
) |
|
|
(37 |
) |
|
|
(25 |
) |
|
|
(44 |
) |
|
|
(127 |
) |
|
|
(42 |
) |
Securities Litigation
(charge) credit, net |
|
|
(52 |
) |
|
|
|
|
|
|
(1 |
) |
|
|
8 |
|
|
|
(45 |
) |
|
|
|
|
|
|
|
Income from Continuing
Operations, Before
Income Taxes |
|
$ |
281 |
|
|
$ |
261 |
|
|
$ |
343 |
|
|
$ |
380 |
|
|
$ |
1,265 |
|
|
$ |
307 |
|
|
|
|
Segment Operating Profit
Margin: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
Solutions |
|
|
1.52 |
% |
|
|
1.24 |
% |
|
|
1.43 |
% |
|
|
1.61 |
% |
|
|
1.45 |
% |
|
|
1.31 |
% |
Medical-Surgical
Solutions |
|
|
4.40 |
|
|
|
3.94 |
|
|
|
4.78 |
|
|
|
3.15 |
|
|
|
4.07 |
|
|
|
3.81 |
|
Provider Technologies |
|
|
8.86 |
|
|
|
7.22 |
|
|
|
9.48 |
|
|
|
11.14 |
|
|
|
9.27 |
|
|
|
8.39 |
|
|
32
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
Financial Condition, Liquidity, and Capital Resources
Operating activities
provided cash of $685 million and $2,002 million during the
first halves of
2007 and 2006. Operating activities for 2007 benefited from improved accounts receivable
management, reflecting changes in our customer mix, our termination of a customer contract, and an
increase in accounts payable associated with improved payment terms.
These benefits were partially offset by increases in inventory needed to support our growth.
Cash flows from operations in 2006
benefited from improved working capital balances for our U.S. pharmaceutical distribution business
as purchases from certain of our suppliers were better aligned with customer demand and as a
result, net financial inventory (inventory net of accounts payable) decreased. Operating
activities for 2006 also benefited from better inventory management and favorable timing in our
working capital accounts, including the timing of a receipt from a large customer and payments to
certain vendors. Cash flows from operations can be significantly impacted by factors such as the
timing of receipts from customers and payments to vendors. Operating activities for 2006 also
include a $143 million cash receipt in connection with an amended agreement entered into with a
customer and cash settlement payments of $69 million for certain Securities Litigation cases.
Investing activities
utilized cash of $95 million and $652 million during the
first halves of
2007 and 2006. Investing activities for 2007 reflect payments of $95 million for our business
acquisitions, $36 million for our investment in Parata, and a $19 million transfer of cash to an
escrow account for a settlement of a Securities Litigation case. Investing activities for 2007
also reflect $175 million of cash proceeds from the sale of our businesses, including $164 million
for the sale of our Acute Care business. Investing activities for 2006 reflect payments of $573
million for our business acquisitions, including D&K and Medcon, and cash proceeds of $63 million
pertaining to the sale of BioServices.
Financing activities
utilized cash of $475 million and $155 million in the first
halves of 2007
and 2006. Financing activities for 2007 include an incremental use of cash of $369 million for
stock repurchases and $91 million less cash receipts resulting from employees exercises of stock
options. Financing activities for 2006 also included $102 million of cash paid for the repayment
of life insurance policy loans.
The Companys Board of Directors (the Board) approved share repurchase plans in October
2003, August 2005, December 2005 and January 2006 which permitted the Company to repurchase up to a
total of $1 billion ($250 million per plan) of the Companys common stock. Under these plans, we
repurchased 19 million shares for $958 million during 2006 and as of March 31, 2006, less than $1
million of these plans remained available for future repurchases.
In April and July 2006, the Board approved share repurchases plans which permitted the Company
to repurchase up to an additional $1 billion ($500 million per plan) of the Companys common stock.
In the second quarter and the first half of 2007, we repurchased a total of 7 million and 13
million shares for $372 million and $656 million, and $345 million remains available for future
repurchases as of September 30, 2006. Repurchased shares will be used to support our stock-based
employee compensation plans and for other general corporate purposes. Stock repurchases may be
made from time to time in open market or private transactions.
Selected Measures of Liquidity and Capital Resources
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
March 31, |
(Dollars in millions) |
|
2006 |
|
2006 |
|
Cash and cash equivalents |
|
$ |
2,254 |
|
|
$ |
2,139 |
|
Working capital |
|
|
3,372 |
|
|
|
3,507 |
|
Debt, net of cash and cash equivalents |
|
|
(1,270 |
) |
|
|
(1,148 |
) |
Debt to capital ratio (1) |
|
|
14.3 |
% |
|
|
14.4 |
% |
Return on stockholders equity (2) |
|
|
14.0 |
|
|
|
13.1 |
|
|
|
|
|
(1) |
|
Ratio is computed as total debt divided by total debt and stockholders equity. |
|
(2) |
|
Ratio is computed as net income (loss) over the past four quarters, divided by a five-quarter
average of stockholders equity. |
Working capital primarily includes cash and cash equivalents, receivables, inventories,
drafts and accounts payable, and deferred revenue. Our Pharmaceutical Solutions segment requires a
substantial investment in working
33
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
capital that is susceptible to large variations during the year
that are a result of a number of factors, including inventory purchase activities, seasonal
demands, customer and supplier mix and the timing of receipts from customers and payments to
suppliers. Inventory purchase activities are a function of sales volume, product mix, new customer
build-up requirements and a level of investment inventory. As of September 30, 2006, consolidated
working capital decreased slightly from March 31, 2006, as working capital needed to support our
growth and increases in our cash and cash equivalent balances were more than offset by favorable
changes in our customer and supplier mix.
During the first quarter of 2006, we called for the redemption of the Companys convertible
junior subordinated debentures, which resulted in the exchange of the preferred securities for 5
million shares of our newly issued common stock.
Credit Resources
We fund our working capital requirements primarily with cash, short-term borrowings and our
receivables sale facility. We have a $1.3 billion five-year, senior unsecured revolving credit
facility that expires in September 2009. Borrowings under this credit facility bear interest at a
fixed base rate, a floating rate based on the London Interbank Offering Rate (LIBOR) rate or a
Eurodollar rate. In June 2006, we renewed our committed accounts receivable sales facility. The
facility was renewed under substantially similar terms to those previously in place with the
exception that the facility was reduced to $700 million from $1.4 billion. The renewed facility
expires in June 2007. No amounts were outstanding under any of these facilities at
September 30, 2006.
Our various borrowing facilities and long-term debt are subject to certain covenants. Our
principal debt covenant is our debt to capital ratio, which cannot exceed 56.5%. If we exceed this
ratio, repayment of debt outstanding under the revolving credit facility and $235 million of term
debt could be accelerated. At September 30, 2006, this ratio was 14.3% and we were in compliance
with our other financial covenants. A reduction in our credit ratings or the lack of compliance
with our covenants could negatively impact our ability to finance operations through our credit
facilities, or issue additional debt at the interest rates then currently available.
Funds necessary for the resolution of the Securities Litigation, future debt maturities and
our other cash requirements are expected to be met by existing cash balances, cash flows from
operations, existing credit sources and other capital market transactions.
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS
In addition to historical information, managements discussion and analysis includes certain
forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as
amended and section 21E of the Securities Exchange Act of 1934, as amended. Some of the
forward-looking statements can be identified by use of forward-looking words such as believes,
expects, anticipates, may, will, should, seeks, approximates, intends, plans, or
estimates, or the negative of these words, or other comparable terminology. The discussion of
financial trends, strategy, plans or intentions may also include forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results to
differ materially from those projected. Although it is not possible to predict or identify all
such risks and uncertainties, they may include, but are not limited to, the following factors. The
readers should not consider this list to be a complete statement of all potential risks and
uncertainties.
|
|
adverse resolution of pending shareholder litigation regarding the 1999 restatement of our historical financial
statements; |
|
|
|
the changing U.S. healthcare environment, including changes in government regulations and the impact of potential
future mandated benefits; |
|
|
|
competition; |
|
|
|
changes in private and governmental reimbursement or in the delivery systems for healthcare products and services; |
|
|
|
governmental and manufacturers efforts to regulate or control the pharmaceutical supply chain; |
34
McKESSON CORPORATION
FINANCIAL REVIEW (Continued)
(Unaudited)
|
|
changes in pharmaceutical and medical-surgical manufacturers pricing, selling, inventory, distribution or supply
policies or practices; |
|
|
|
changes in the availability or pricing of generic drugs; |
|
|
|
changes in customer mix; |
|
|
|
substantial defaults in payment or a material reduction in purchases by large customers; |
|
|
|
challenges in integrating and implementing the Companys internally used or externally sold software and software
systems, or the slowing or deferral of demand or extension of the sales cycle for external software products; |
|
|
|
continued access to third-party licenses for software and the patent positions of the Companys proprietary software; |
|
|
|
the Companys ability to meet performance requirements in its disease management programs; |
|
|
|
the adequacy of insurance to cover liability or loss claims; |
|
|
|
new or revised tax legislation; |
|
|
|
foreign currency fluctuations or disruptions to foreign operations; |
|
|
|
the Companys ability to successfully identify, consummate and integrate strategic acquisitions; |
|
|
|
changes in generally accepted accounting principles (GAAP); and |
|
|
|
general economic conditions. |
These and other risks and uncertainties are described herein or in our Forms 10-K, 10-Q, 8-K
and other public documents filed with the Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date hereof. We undertake no obligation to publicly release the result of any revisions to
these forward-looking statements to reflect events or circumstances after this date or to reflect
the occurrence of unanticipated events.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We believe there has been no material change in our exposure to risks associated with
fluctuations in interest and foreign currency exchange rates discussed in our 2006 Annual Report on
Form 10-K.
Item 4. Controls and Procedures
Our Chief Executive Officer and our Chief Financial Officer, after evaluating the
effectiveness of the Companys disclosure controls and procedures (as defined in the Exchange Act
Rules 13a-15(e)) as of the end of the period covered by this quarterly report, have concluded that
our disclosure controls and procedures are effective
based on their evaluation of these controls and procedures required by paragraph (b) of
Exchange Act Rules 13a-15 or 15d-15.
There were no changes in our internal control over financial reporting identified in
connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15
that occurred during our last fiscal quarter that have materially affected, or are reasonably
likely to materially affect, our internal controls over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
See
Financial Note 14, Other Commitments and Contingent Liabilities, of our unaudited
condensed consolidated financial statements contained in Part I of this Quarterly Report on Form
10-Q.
Item 1A. Risk Factors
There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our
2006 Form 10-K.
35
McKESSON CORPORATION
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information on the Companys share repurchases during the second
quarter of 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Repurchases |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate |
|
|
|
|
|
|
|
|
|
|
|
Total Number of |
|
|
Dollar Value of |
|
|
|
|
|
|
|
|
|
|
|
Shares Purchased |
|
|
Shares that May |
|
|
|
|
|
|
|
|
|
|
|
As Part of Publicly |
|
|
Yet Be Purchased |
|
|
|
Total Number of |
|
|
Average Price Paid |
|
|
Announced |
|
|
Under the |
|
(In millions, except price per share) |
|
Shares Purchased |
|
|
Per Share |
|
|
Program |
|
|
Programs(1) |
|
|
July 1, 2006 July 31, 2006 |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
$ |
717 |
|
August 1, 2006 August 31, 2006 |
|
|
5 |
|
|
|
51.36 |
|
|
|
5 |
|
|
|
475 |
|
September 1, 2006 September 30, 2006 |
|
|
2 |
|
|
|
52.52 |
|
|
|
2 |
|
|
|
345 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
7 |
|
|
|
51.76 |
|
|
|
7 |
|
|
|
345 |
|
|
|
|
|
(1) |
|
In April and July 2006, the Companys Board of Directors approved plans to repurchase up to
a total of $1 billion ($500 million per plan) of the Companys common stock. These plans have no expiration date.
This table does not include shares tendered to satisfy the exercise price in connection with
cashless exercises of employee stock options or shares tendered to satisfy tax withholding
obligations in connection with employee equity awards. |
Item 3. Defaults Upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Security Holders
The Companys Annual Meeting of Stockholders was held on July 26, 2006. The following matters
were voted upon at the meeting and the stockholder votes on each such matter are briefly described
below.
The Board of Directors nominees for directors as listed in the proxy statement were each
elected to serve for a three-year term. The vote was as follows:
|
|
|
|
|
|
|
|
|
|
|
Votes For |
|
Votes Withheld |
Wayne A. Budd |
|
|
268,287,029 |
|
|
|
3,915,414 |
|
Alton F. Irby III |
|
|
264,587,973 |
|
|
|
7,614,470 |
|
David M. Lawrence, M.D. |
|
|
266,715,464 |
|
|
|
5,486,979 |
|
James V. Napier |
|
|
266,829,089 |
|
|
|
5,373,354 |
|
The term of the following directors continued after the meeting:
|
|
|
John H. Hammergren
|
|
M. Christine Jacobs |
Marie L. Knowles
|
|
Robert W. Matschullat |
Jane E. Shaw |
|
|
The proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered
public accounting firm for the year ending March 31, 2007 received the following vote:
|
|
|
|
|
Votes For |
|
Votes Against |
|
Votes Abstained |
269,175,565
|
|
1,113,064
|
|
1,913,814 |
Stockholder proposal to adopt a policy that we elect each Director annually received the
following vote:
|
|
|
|
|
|
|
Votes For |
|
Votes Against |
|
Votes Abstained |
|
Broker Non Vote |
208,494,813
|
|
30,700,121
|
|
3,026,182
|
|
29,981,327 |
36
McKESSON CORPORATION
Item 5. Other Information
Internal Revenue Code Section 409A (Code Section 409A) affects the way nonqualified
deferred compensation plans are designed and administered and is effective with respect to amounts
deferred, vested or accrued after December 31, 2004. On October 27, 2006, the Compensation
Committee of the Board of Directors (the Compensation Committee) of McKesson Corporation (the
Company) approved the amendment and restatement of the Companys Severance Policy for Executive
Employees, the 2005 Stock Plan and the Executive Benefit Retirement Plan, each effective January 1,
2005 primarily to conform the plans to the requirements of Code Section 409A. In addition to the
changes required by code Section 409A, the Compensation Committee amended the Executive Benefit
Retirement Plan to provide for a lump sum payment as the default form of payment upon retirement from the Company and the Severance Policy for Executive Employees to provide
for reimbursement of COBRA premium payments during the
severance period and to expand eligibility by allowing the Compensation Committee to designate
certain non-executive employees as eligible employees under the policy.
Also in response to Code Section 409A, on October 27, 2006, the Board of Directors of the
Company approved the amended and restated Long Term Incentive Plan and adopted two new nonqualified
deferred compensation plans, the Deferred Compensation Plan III (DCAP III) and the Supplemental
PSIP II. Both plans are successor plans to existing Company nonqualified deferred compensation
plans, and all three plans are intended to comply with Code Section 409A.
In addition, on October 27, 2006, the Board approved a new plan, the Change in Control Policy
for Selected Executive Employees (the Change in Control Policy), effective November 1, 2006. The
Change in Control Policy provides severance payments to certain
employees of the Company (including executive officers) upon separation from service, without cause
(as defined in the policy) or for good reason (as defined in the policy), as the result of a change
in control of the Company. The Change in Control Policy replaces any individual agreements between
the Company and its officers with respect to change in control benefits (except with respect to Mr.
Hammergren, Mr. Julian and Ms. Pure, each of whom has a written employment agreement with the
Company as described below) and expands eligibility for benefits to a larger employee group.
Participants in the Change in Control Policy are designated by the Compensation Committee to
participate in one of three tiers. Tier one participants are entitled to a cash benefit equal to
2.99 times earnings (as defined in the policy), tier two participants are entitled to a cash
benefit equal to two times earnings and tier three participants are entitled to a cash benefit
equal to one times earnings. Change in Control Policy participants are eligible for a gross-up
payment if the change in control benefits paid under the policy are subject to an excise tax under
Internal Revenue Code Section 4999. In addition, if a tier one participant is covered by the
Executive Benefit Retirement Plan, his or her straight life annuity benefits under that plan will
be calculated by adding three additional years of age and three additional years of service to the
participants actual age and service. Tier one participants are eligible for three years of
continued coverage under the applicable health and life insurance plans, tier two participants are
eligible for two years of continued coverage and tier three participants for one year of continued
coverage. All participants are eligible for outplacement services as determined by the Executive
Vice President, Human Resources.
Also in response to Code Section 409A, on October 27, 2006, the Compensation Committee
approved amended and restated employment agreements with its executive officers John Hammergren
(Chairman, President and Chief Executive Officer), Paul Julian (Executive Vice President and Group
President) and Pamela Pure (Executive Vice President and President, McKesson Provider
Technologies). Each employment agreement has a new initial three-year term. The employment
agreements were amended and restated primarily to conform to the requirements of Code Section 409A;
however, additional amendments were made. Specifically each employment agreement has been updated
to address state law considerations with respect to the non-competition, non-solicitation and
nondisclosure covenants.
Other amendments made to the employment agreements include the following:
|
|
The Company, in consultation and agreement with the executive, has the authority to delay or restructure payments under
the agreement to avoid triggering tax and interest penalties under Code Section 409A; |
|
|
|
To the extent that severance payments or benefits payable under the agreements are subject to the Code Section 409A
required delay in payment to specified employees, the deferred compensation will earn interest at the crediting rate
provided for in DCAP III during the delayed payment period; |
|
|
|
The Company agrees to indemnify the executive for any liability that he or she may incur under Code Section 409A as a
direct result of the Companys failure to administer the employment agreement in compliance with
|
37
McKESSON CORPORATION
|
|
Code Section 409A.
The executive would not be indemnified for any liability that he or she incurs under Code Section 409A as a result of
his or her own willful acts or omissions; and |
|
|
|
The provisions of the Change in Control Policy (described above) are included in the amended employment agreements.
|
Mr. Julians and Ms. Pures employment agreements were further amended to provide the
following benefits upon the executives separation from service (without cause or for good reason)
as a result of a change in control: tier one change in control benefits as described in the Change
in Control Policy; continued medical coverage; acceleration of long-term incentives (as provided in
the Companys long-term incentive plans); and a gross-up payment if the change in control benefits
are subject to excise tax under Internal Revenue Code Section 4999. Finally, pursuant to Mr.
Julians employment agreement, his target incentive under the 2005 Management Incentive Plan of
McKesson Corporation has been increased to 110% for Fiscal Year 2008.
Also on October 27, 2006, following a comprehensive review of compensation practices and
levels for non-employee directors, the Board of Directors approved an increase in the annual
retainer for non-employee directors to $75,000, and an increase in the Committee Chair annual
retainers of $5,000 which will result in a $20,000 annual retainer for the Chair of the Audit
Committee and $10,000 for each of the Chairs of the Finance Committee and the Committee on
Directors and Corporate Governance. The annual retainer for the Chair of the Compensation
Committee was increased to $20,000 from $5,000. These changes became effective on October 1, 2006.
No further changes were made to the non-employee directors compensation program.
Additionally, an annual retainer of $10,000 was established for the Presiding Director
effective July 25, 2007. The role of Presiding Director is rotated annually among the Committee
Chairs.
Item 6. Exhibits
|
|
|
Exhibit |
|
|
Number |
|
Description |
10.10
|
|
McKesson Corporation Executive Benefit Retirement Plan, amended and restated effective
as of October 27, 2006. |
|
|
|
10.13
|
|
McKesson Corporation Severance Policy for Executive Employees, amended and restated
effective as of January 1, 2005. |
|
|
|
10.14
|
|
McKesson Corporation 2005 Management Incentive Plan, amended and restated effective as
of October 27, 2006. |
|
|
|
10.15
|
|
McKesson Corporation Long-Term Incentive Plan, as amended and restated effective as of
January 1, 2005. |
|
|
|
10.21
|
|
McKesson Corporation 2005 Stock Plan, amended and restated effective as of May 25, 2005. |
|
|
|
10.30
|
|
Amended and Restated Employment
Agreement, effective as of November 1, 2006, by and
between McKesson Corporation and its Chairman, President and Chief Executive Officer. |
|
|
|
10.31
|
|
Amended and Restated Employment
Agreement, effective as of November 1, 2006, by and
between McKesson Corporation and its Executive Vice President and President, McKesson
Provider Technologies. |
|
|
|
10.32
|
|
Amended and Restated Employment
Agreement, effective as of November 1, 2006, by and
between McKesson Corporation and its Executive Vice President and Group President. |
|
|
|
10.33
|
|
McKesson Corporation Change in Control Policy for Selected Executive Employees,
effective as of November 1, 2006. |
|
|
|
10.34
|
|
McKesson Corporation Deferred Compensation Administration Plan III (DCAP III),
effective as of January 1, 2005. |
|
|
|
10.35
|
|
McKesson Corporation Supplemental PSIP II, effective as of January 1, 2005. |
|
|
|
31.1
|
|
Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of
1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
31.2
|
|
Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of
1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
38
McKESSON
CORPORATION
|
|
|
Exhibit |
|
|
Number |
|
Description |
32
|
|
Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002. |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
|
|
|
McKesson Corporation
|
|
Dated: November 1, 2006 |
/s/ Jeffrey C. Campbell
|
|
|
Jeffrey C. Campbell |
|
|
Executive Vice President and Chief
Financial Officer |
|
|
|
|
|
|
/s/ Nigel A. Rees
|
|
|
Nigel A. Rees |
|
|
Vice President and Controller |
|
39